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ABSTRACT 
 
DIO KAVALIERATOS: Exploring the Role of Palliative Care in Heart Failure:  
Referral Barriers, Care Gaps, and Quality of Care 
(Under the direction of Morris Weinberger, Ph.D.) 
 
Heart failure is a chronic, incurable disease that presents significant burdens to 
patients, caregivers, and the healthcare system. With approximately 5 million 
Americans currently diagnosed with heart failure, the effective management of heart 
failure patients is of prime interest to clinicians, policymakers, and payers. Palliative 
care, which has been shown to improve patient outcomes in cancer, may hold similar 
promise for heart failure patients. However, despite similar disease experiences and 
prognosis, heart failure patients are less likely to receive palliative care than cancer 
patients. This dissertation investigates the current and potential role of specialist 
palliative care in heart failure.  
Through the use of mixed qualitative and quantitative methodologies, the three 
papers in this dissertation provide contributions to the medical literature related to: (1) 
palliative care referral barriers in heart failure; (2) the unresolved symptoms and 
treatment gaps of heart failure patients prior to palliative care consultation; and, (3) the 
link between palliative processes and patient outcomes in a cohort of heart failure 
patients receiving community-based palliative care.  
Our findings suggest that the term “palliative care” is ambiguous to providers 
and itself may stand as a barrier to referral. Nevertheless, we documented agreement 
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among primary care, cardiology, and palliative care providers regarding the likely 
potential benefit of palliative services in advanced heart failure. Next, we found that 
among a group of heart failure and cancer patients receiving palliative care, both 
groups possessed significant palliative needs. Furthermore, the profiles of burden were 
not strikingly different between disease groups, thereby suggesting that the need for 
palliative care is similar for patients living with either illness. Lastly, we present data 
regarding the impact of palliative care in a cohort of heart failure patients. Of five quality 
indicators, the completion of a comprehensive assessment was found to be associated 
with improved patient health.  
In sum, this dissertation provides a glimpse into the needs of HF patients and 
how they might be addressed by specialist palliative care. Our work suggests that in 
heart failure, palliative care is underutilized, that patients have unmet needs, and that 
specific palliative interventions such as comprehensive assessment should be 
prioritized.  
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PREFACE 
 
This dissertation is structured to follow the 3-paper format. As such, Chapters 1 
and 2 offer an introduction to the overall dissertation study, as well as provide the 
requisite review of the literature. Chapter 3 broadly describes the analytic methods used 
in each of the three dissertation studies. Next, Chapters 4-6 each contain standalone 
manuscripts that have been prepared for submission to biomedical journals. As such, 
repetition and redundancy may be evident across Chapters. Lastly, Chapter 7 
synthesizes the findings of the dissertation studies, places this synthesis within the 
context of current and future trends in medicine, and offers implications for future policy, 
practice, and research.  
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CHAPTER 1: INTRODUCTION AND SPECIFIC AIMS 
 
Heart failure (HF) is a prevalent, irreversible, and progressive disease that leads 
to morbidity, hospitalizations, health care costs, and death. Furthermore, research 
suggests that HF patients experience physical and emotional distress throughout their 
course of illness and increasingly so toward the end of life;1 such distress may be 
addressed by palliative care. However, due to lack of research in this area, the specific 
mechanisms by which palliative care might confer benefit to HF patients and their 
caregivers remains unknown. Palliative care seeks to improve quality of life for those 
individuals suffering from life-limiting illnesses and their families. Through 
multidisciplinary intervention, palliative care provides symptom management, 
psychological and spiritual support, and logistical assistance with care coordination and 
planning.2 Research suggests that palliative care improves satisfaction with care;3 
decreases the risk of patient depression3 and complicated bereavement for family 
caregivers;4,5 reduces patients’ symptom intensity;6 lowers rates of intensive care unit 
(ICU) admissions;7 and, reduces hospital expenditures.8  
The long-term goal of this line of research is to enhance the quality of care for 
and to improve the outcomes of patients with advanced HF. As such, this dissertation 
comprises three specific aims described below: 
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Aim 1 To identify potential provider-related barriers to referring patients with HF 
for palliative care 
Sub-aim 1.1 To explore physician and non-physician provider (cardiologist, 
primary care, and palliative medicine) knowledge, attitudes, experiences, and potential 
barriers regarding palliative care, in general, as well as specifically related to HF 
Sub-aim 1.2 To elicit provider perceptions of the components that comprise 
high-quality advanced HF care  
Sub-aim 1.3 To explore provider attitudes regarding palliative care quality 
metrics and their relevance to advanced HF care  
 
Aim 2 To assess and compare unresolved symptoms and treatment gaps 
between HF and cancer patients referred for community-based palliative care  
Sub-aim 2.1 To identify unaddressed symptoms and treatment gaps 
experienced by HF and cancer patients at first palliative care consultation  
Sub-aim 2.2  To determine whether differences in unresolved symptom and 
treatment gap prevalence can be explained by primary disease (i.e., HF or cancer) 
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Aim 3 To describe patient-centered outcomes for patients with HF and cancer 
referred for community-based palliative care and the association between 
outcomes and quality indicators 
Sub-aim 3.1 To describe patient-centered outcomes in HF and cancer patients 
receiving community-based palliative care, and investigate any differences between the 
two cohorts  
Sub-aim 3.2 To assess the association between palliative care quality 
indicators and patient-centered outcomes  
 
Findings from this study can be used to: (1) inform future research to develop a 
model of palliative care that is appropriate for HF; (2) examine potential disparities in 
palliative care access and uptake in HF; and (3) demonstrate the clinician-perceived 
relevance of palliative care quality indicators and their association to meaningful patient-
centered outcomes.  By assessing the barriers and outcomes related to the palliation of 
HF, this work may encourage discussion of the applicability of the current cancer-
focused palliative care model to other non-neoplastic diseases (e.g., chronic obstructive 
pulmonary disease, renal disease, AIDS).  In sum, this dissertation investigates issues of 
quality and access to palliative care within HF, a disease population whose needs are 
believed to be under-recognized relative to cancer, using a mixed methods approach.  
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CHAPTER 2: BACKGROUND AND SIGNIFICANCE 
 
Heart failure is a prevalent and chronic disease, representing a significant portion of U.S. 
healthcare utilization and expenditures 
HF is an increasingly prevalent disease that affects approximately 5.8 million 
Americans, with more than 550,000 new cases diagnosed yearly.1 The current lifetime 
risk of developing HF is 1 in 5 for those individuals older than age 40.2 The one-year 
mortality from HF rivals the risk for most cancers, ranging from 50-70%.3 Especially in its 
advanced stages, HF is a particularly costly disease. The estimated direct and indirect 
cost of HF in the United States (U.S.) during 2010 is $39.2 billion.4 HF is responsible for 
12-15 million outpatient visits per year.5 Hospital discharges related to HF increased 
from 877,000 to 1,106,000 between 1996 and 2006.1 HF is the leading cause of 
hospitalization among Medicare beneficiaries,6 and nearly half of these stays exceed 
diagnosis-related groups reimbursement averages, making it the costliest disease in the 
Medicare population.7,8 Additionally, HF patients are likely to spend twice as many days 
in intensive care units than all other patients.8 Given the disproportionate prevalence of 
HF in the Medicare-eligible population,1 the issues of cost, quality, and access to care 
are of prime relevance to policymakers.  
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What is palliative care and how can it improve the HF illness experience? 
Palliative care seeks to improve quality of life for those individuals suffering from 
serious or life-limiting illness, and to support families throughout the disease experience. 
Through multidisciplinary intervention, palliative care achieves its aims by: expert 
assessment and treatment of pain and other symptoms; psychological and spiritual 
support; care coordination; support for complex and difficult medical decisions; 
assistance in communicating and setting goals related to care; and, bereavement 
support for families.9 Figure 2.1 provides a graphical depiction of how palliative care 
might be leveraged to improve HF patient outcomes.   
Non-hospice palliative care is critically distinct from “hospice” care.  Whereas 
being a part of palliative care, “hospice” care specifically targets patients entering the 
terminal phase of their lives. Eligibility under the Medicare Hospice Benefit requires 
physician certification of expected prognosis less than 6 months, as well as patient 
agreement to forego insurance coverage for curative or life-prolonging therapies. 
Conversely, non-hospice palliative care (hereinafter, “palliative care”) may be initiated at 
any point post-diagnosis, and may be provided concurrently with curative or life-
prolonging therapies. In contrast, palliative care focuses on the optimization of patient 
and family quality of life (QOL), regardless of disease stage or prognosis. As defined by 
the National Consensus Project for Quality Palliative Care, “Palliative care expands 
traditional disease-model medical treatments to include the goals of enhancing quality of 
life for patient and family, optimizing function, helping with decision making, and 
providing opportunities for personal growth… Palliative care aims to guide and assist the 
patient and family in making decisions that enable them to work toward their goals 
during whatever time they have remaining.” In sum, all hospice care is palliative; 
however, palliative care is not necessarily hospice care. The current research focuses 
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on palliative care in its entirety, which by definition will include patients receiving hospice 
services.  
Research has shown that palliative care improves satisfaction with care;10 
decreases the risk of patient depression10 and complicated bereavement for family 
caregivers;11,12 and increases the likelihood of an at-home death.13 Furthermore, 
evidence suggests that palliative care consultations decrease healthcare utilization and 
expenditures at the end of life. A recent multi-site study demonstrated an adjusted net 
savings of $4,908 in direct costs per admission and $374 in direct costs per day for 
recipients of palliative care compared to propensity score-matched control subjects.14 
Such savings may result from a decrease in the number of procedures performed,15 
length of hospitalizations,16 and length of intensive care unit stays15 near the end of life.  
Research suggests that HF patients experience significant physical and 
emotional distress that may be addressed by palliative care. Regrettably, symptoms 
experienced by HF patients may go unrecognized and unaddressed.17 Whereas 
dyspnea and fatigue are considered to be characteristic of HF,18 numerous studies 
suggest that patients may suffer from symptoms including pain, depression, anxiety, 
edema, and constipation.18-20 For example, in a study of U.S. veterans with HF, 55.2% 
reported pain; of those individuals, more than half noted their pain as moderate to 
severe.21 As such, current guidelines from the American College of Cardiology and the 
American Heart Association recommend palliative care and/or hospice referral for HF 
patients, especially in advanced stages of disease.5  
HF poses an excellent disease model in which to study the potential effects of 
palliative care for several reasons. First, given that HF patients commonly experience 
multi-morbidity and frequently receive care from numerous providers, the role of 
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palliative care as a care coordination entity may be pivotal. Second, palliative care’s 
focus on clear communication regarding prognosis and the setting of care goals may 
serve to reduce potentially unnecessary emergency department, hospital inpatient, and 
intensive care unit utilization. Indeed, a source of anxiety for HF patients is the unclear 
guidance regarding how to manage such events.22   
 
HF and cancer are remarkably similar in advanced stages, yet disparities exist regarding 
receipt of supportive services 
 
Hospice enrollment statistics demonstrate that despite higher prevalence and 
similar late-stage prognosis, fewer HF patients access such supportive services than do 
cancer patients; non-hospice palliative care statistics are currently unavailable.23 In 
2008, cancer was the leading diagnosis among hospice enrollees (38.3%), whereas HF 
ranked 3rd (11.7%).24 Given that the physical, psychological, and spiritual needs of 
advanced HF patients are similar to those needs of cancer patients,19,25 we must 
question whether systems- or provider-level barriers can explain why they appear to 
underuse palliative care. A recent systematic review regarding symptom burden in five 
advanced diseases suggests that the heart disease illness burden may not be entirely 
unique from cancer illness burden, for example.25 As noted by the authors, pain, 
dyspnea, and fatigue were present in more than 50% of patients from all five diseases, 
lending credence to the notion of “common final pathways” at the end-of-life.  
Interestingly, a recent analysis of 513 cancer patients receiving palliative care in 
North Carolina documented a striking number of care gaps experienced by such 
patients.26 For example, of 10 symptoms assessed 95% of these patients reported the 
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presence of one symptom, and 67% reported three or more symptoms. Additionally, it 
was frequently the case that patients were not receiving interventions for distressing 
symptoms (e.g., only 25% of patients reporting moderate or severe constipation were 
receiving related treatment). It is critical to note that these symptoms were assessed at 
patients’ first palliative care visit and were only counted if reported at a level of at least 
“moderately problematic.” The presence of such distressing and uncontrolled symptoms 
at the time of palliative care initiation may suggest inadequate focus on symptom 
management prior to palliative care referral. Though not confirmable at present, it is 
plausible that such gaps in care are experienced more frequently by HF patients for two 
reasons: 1) cancer patients may be more likely to be comprehensively screened for 
symptoms, as seen by previous references to under-recognition of distressing HF 
symptoms; and, 2) cancer patients are more likely to receive hospice services than are 
HF patients, proportionally speaking.  
 Barriers related to uptake of palliative care in HF populations 
Several factors appear to be related to the low rates of palliative care enrollment 
by HF patients, including: the unpredictable disease trajectory of HF;27-29 the view of HF 
as a chronic, manageable disease;27,28 and patient and caregiver confusion regarding 
prognosis.30  Several qualitative studies exploring physician-related palliative care 
referral barriers for patients with HF in the U.K. suggest organizational, professional, and 
cognitive factors potentially at play.29,31 However, given differences in healthcare delivery 
systems, reimbursement policy, and culture, it is important to explore barriers to referral 
in the U.S. By examining provider perceptions regarding palliative care for HF, we may 
discover barriers explaining the relatively low rate of palliative care uptake by HF 
patients. I believe the physician aspect to be critically relevant due to the fact that 
palliative care is most often a consult service, many times requiring physician referral.  
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Quality assessment in palliative care  
Historically, rigorous quality monitoring and research efforts have not been 
priorities of the hospice and palliative medicine disciplines.32 Issues motivating this 
paucity of research include: the relative infancy of hospice and palliative medicine in the 
U.S., a lack of standardized research and quality improvement practices across the field, 
and logistical concerns related to conducting interventional research with terminal 
patients.33 Recently, there has been an increased focus on the quality of care received 
by individuals in advanced or terminal stages of illness. Perhaps most impressively, the 
Patient Protection and Affordable Care Act (PPACA) includes a mandate requiring the 
Centers for Medicare and Medicaid Services (CMS) to publish hospice quality measures 
by October 1, 2012. Hospices that fail to report quality data will receive a 2 percentage-
point reduction in payments beginning in fiscal year 2014.34 It is expected that this 2-
percentage-point margin will be converted into bonuses and penalties related to quality 
performance at some point thereafter.34 Additionally, PPACA mandates that CMS begin 
to test value-based purchasing in hospice no later than January 1, 2016.  Though the 
focus of such efforts has been hospice care, any hospice-focused quality efforts 
naturally affect the non-hospice palliative care community given the high degree of 
interconnectedness between the two entities.  
In 2006, CMS contracted the Carolinas Center for Medical Excellence to address 
quality assessment and improvement in hospice and palliative care.35 The purpose of 
this initiative was to provide guidance for hospice programs to begin systematically 
collecting and monitoring quality of care, in preparation for Quality Assessment and 
Performance Improvement (QAPI) program participation. As such, this project sought to: 
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a) compile a set of quality metrics for hospice and palliative medicine; b) provide 
resources such as validated instruments and scales; and, c) suggest strategies for 
quality monitoring and improvement. Guiding their work, Schenck and colleagues 
followed a framework previously used by the National Consensus Project for Palliative 
Care Quality.36 This framework defines eight domains of palliative care, as well as 38 
related preferred practices; this work was subsequently endorsed by the National Quality 
Forum in 2006. The authors first conducted a focused literature search of the scientific 
and gray literature, including metrics used by governmental entities and national 
hospice/palliative care organizations. To be included, metrics had to explicitly define 
their numerators and denominators, and could not have been developed solely for 
research purposes. Furthermore, the authors chose metrics that aligned with a care 
process or outcome identified by the National Consensus Project, and those metrics that 
could be applied across the various care settings of hospice and palliative medicine. 
After filtering for appropriateness, the authors convened a 14-member expert panel to 
rate each of the 86 identified metrics on four criteria: importance, scientific soundness, 
usability, and feasibility. Average scores were calculated for each metric, and those 
ranking above the 75th percentile were ultimately selected. Additional metrics were 
added based on “high” importance scores, despite being below the 75th percentile, 
yielding a total of 34 metrics. The result of this project, known as the PEACE (Prepare, 
Embrace, Attend, Communicate, Empower) metric set, was used in this dissertation.   
A recent white paper by Kamal and colleagues summarizes the results of a 
literature review related to quality indicators in palliative and end-of-life care.37 The 
authors describe 12 sets of quality measures, which comprise 281 individual metrics; 
one of these sets was the PEACE set. After comparing all available metric sets, I 
ultimately chose the PEACE set due to its general focus (versus disease- or setting-
 12 
specific focus), as well as its close connection to policy, being that it is the product of a 
CMS mandate.  
 
Summary 
Uncontrolled symptom distress and unaddressed psychosocial needs within HF 
pose a target for the multidisciplinary expert management from palliative medicine. 
Regrettably, prior research has shown that for a variety of potential reasons, HF patients 
access palliative care at a rate disproportionate to cancer patients, despite striking 
similarities between the two illnesses. The high costs and healthcare utilization 
associated with the typical advanced HF trajectory represent areas of prime interest for 
clinicians, payers, and policymakers, especially in the contemporary climate related to 
healthcare reform. Additional work is necessary to unravel U.S.-specific factors related 
to low palliative care utilization in HF, as well as to establish a knowledge base regarding 
the effectiveness of palliative interventions in this population. This dissertation intends to 
contribute to this very effort. 
In this dissertation, I explored the role of palliative care in HF, focusing on three 
overarching questions: 
• What provider-level factors might serve as barriers to palliative care referral 
among HF patients? (Study 1) 
• When HF patients do receive palliative care consultations, with what 
unaddressed symptoms do they present, and are these care needs different 
than the needs of cancer patients? (Study 2) 
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• Is there an association between specialist palliative care intervention and 
patient outcomes? (Study 3) 
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FIGURES AND TABLES 
 
Figure 2.1: Optimal integration of non-hospice and hospice palliative care with 
standard heart failure treatment across the typical disease trajectory 
Abbreviations: HF, heart failure; ACC/AHA, American College of Cardiology/American 
Heart Association; NYHA, New York Heart Association 
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CHAPTER 3: OVERVIEW OF METHODS 
  
In this dissertation, I sequentially employed qualitative and quantitative methods 
to execute the Specific Aims previously described. Table 3.1 offers a description of the 
methods used in this dissertation.  
 
Aim 1: Palliative care referral barriers in heart failure  
Data for Aim 1 came from two sources, in the following sequence: 1) an internet-
based survey to collect demographic information, as well as providers’ perceptions 
regarding palliative care quality metrics; and, 2) 60-minute semi-structured interviews 
related to various aspects of palliative care and heart failure.   
 
Internet-based survey to evaluate quality indicators 
Subjects 
I chose to include both physician and non-physician providers (i.e., nurse 
practitioners, physician assistants) in this study. Non-physician providers were included 
because: a) they are frequently involved in both cardiac and palliative service provision 
and b) their perspectives will complement views of physicians, resulting in a more 
thorough assessment of this research question. Interview participants were sampled 
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through purposive, referral sampling, with the help of Committee members to identify 
potential interviewees. I recruited participants via email solicitation. To be eligible for this 
study, participants must have been in current practice (i.e., greater than 60% clinical 
time), and must have cared for at least three HF patients in the past six months. To 
increase sample heterogeneity, I enrolled a mix of providers based on: clinical discipline; 
type of provider (i.e., physician versus non-physician); and academic practice affiliation, 
in the following fashion (Table 3.2). Participants were compensated with $50 for 
completing all study-related tasks (i.e., pre-interview questionnaire, and interview).  
 
Measures 
Upon study enrollment, participants were sent a list of 14 PEACE quality 
indicators via email. Participants were asked to reflect on a typical HF patient for whom 
they care, as well as their own practice style. Next, participants were asked to enter a 
Qualtrics® survey website customized for this study, where they chose and rank-ordered 
the top three indicators which they believe: “are likely to be valid indicators of overall 
high-quality HF care, so much so that it would be appropriate on which to base Centers 
for Medicare and Medicaid (CMS) reimbursement decisions (bonuses or penalties).” The 
latter condition is important due to the prospective penalties to be potentially imposed by 
CMS regarding quality performance in palliative care. Indicators were not referred to as 
“palliative care metrics,” rather as “indicators of quality care for patients with life-limiting 
illness, such as heart failure” so as to avoid non-palliative care clinicians from 
disregarding them as irrelevant to their practice. Some indicators were reworded to 
make sense in a non-hospice palliative care context (e.g., increased time intervals 
between visits). Results from the indicator ranking exercise were used to inform Aim 3 of 
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this dissertation. The five highest-ranked indicators were used in regression models to 
assess their association with various patient-centered outcomes.  
The following criteria were used to select the specific PEACE indicators to be 
used in this dissertation: a) the indicator must be assessable with the data available in 
PCRR (Palliative Care Research Registry), the data source for this dissertation; and, b) 
the indicator must be measured at the patient level (i.e., no organizational policy 
metrics). 
Other variables collected in the survey included: general demographics (age, 
race, gender); degree type; additional certifications/training; years in practice; estimated 
current and past year HF patient caseload; and, the most common types of referrals 
made for HF patients.  
 
Semi-structured interviews  
Subjects 
Individuals who completed the pre-interview internet survey described above also 
served as respondents for the semi-structured interviews.  
 
Measures 
Upon completion of the Qualtrics® survey, providers participated in a 60-minute 
interview. Interviews were conducted in a semi-structured format, following the interview 
guide displayed in Figure 3.1. The guide was informed by a review of the previous 
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literature on care transitions in HF, as well as through discussions with three key 
informants: the Medical Director of a HF clinic; a rural, community-based practicing 
cardiologist; and the Director of a HF disease management program.  
The overall objective of the interviews was to ascertain provider knowledge, 
attitudes, and perceptions regarding the use of palliative care services for HF patients. 
Given that palliative care is a supportive service, it is possible that simply asking 
participants whether they endorse palliative care may have yielded socially-desirable 
and biased responses. As such, I indirectly gauged physician endorsement of palliative 
care by constructing interviews around four major themes: (1) hypothetical treatment 
strategy for a New York Heart Association (NYHA) Class III HF patient with significant 
palliative care needs; (2) the balance between survival improvement and symptom 
management in HF; (3) knowledge, attitudes, and experiences with palliative care; and 
(4) barriers to palliative care referral and uptake. To guide discussion related to the first 
theme, I constructed a case of a hypothetical NYHA Class III HF patient with significant 
comorbidities and symptom management needs (Table 4.2). This case was carefully 
constructed to simultaneously present a patient clearly eligible and appropriate for 
palliative care, although not ill enough to prompt automatic referral to hospice (thereby 
bypassing non-hospice palliative care).  
 
Analysis 
Interview data were collected and analyzed following template analysis, a 
qualitative approach that combines the strengths of content analysis and grounded 
theory.1 Whereas purist grounded theory demands an entirely inductive approach to data 
analysis without a priori assumptions, template analysis affords the investigator flexibility 
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to integrate external perspectives (e.g., conceptual framework), for a hybrid 
inductive/deductive theory generation process. Interview transcripts were coded using 
the process of open, axial, and selective coding, performed line-by-line.2 Consistent with 
the qualitative concept of “constant comparison,” text units were compared with 
previously-coded data to challenge the stability and relevance of emergent themes. A 
master codebook was informed by an extensive literature review. Coding was performed 
using NVivo 9, a qualitative data analysis program.3 
Data were analyzed using an assortment of common qualitative techniques, 
including coding dendrograms and matrix queries.4 Quality and rigor of the interviews in 
Aim 1 were addressed following the guidelines of Charmaz, who suggests that attention 
be paid to: credibility, originality, resonance, and usefulness.5 Additionally, confirmability 
of qualitative findings was addressed by having a random 50% (n = 9) sample of 
interview transcripts independently coded by a second analyst, an experienced 
qualitative nursing researcher.6 Consensus meetings were held to resolve coding 
discrepancies, as well as to assist in refining the study’s master codebook. All changes 
made to the codebook were retroactively applied to previously-coded transcripts.  
 
Aim 2: Unaddressed symptoms and treatment gaps at the time of first palliative 
care consult  
Data source  
Data for Aims 2 and 3 were accessed from the Palliative Care Research Registry 
(PCRR), the database of the Carolinas Palliative Care Consortium (hereinafter, the 
Consortium). The PCRR accumulates clinician, patient, and proxy reported data, 
detailing individual patients’ demographics, disease characteristics, symptoms and 
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related interventions. Patient outcomes including QOL, survival, and transition to hospice 
are captured at each visit. Data are collected via paper, tablet computers, or digital pens 
at the point of care. To date, these data have been used for quality monitoring purposes; 
however, the Duke Cancer Care Research Program (DCCRP) (later folded into the 
newly formed Duke Center for Learning Health Care) successfully received approval 
from the Duke University Institutional Review Board so that research analyses may be 
performed with these data. The PCRR is the first, and currently the only, multi-site 
initiative to collect quality performance and outcomes data in community-based palliative 
care. As a proof-of-concept, the PCRR was developed with the explicit intent of 
continuous improvement and refinement, yet required relative simplicity to ensure initial 
buy-in from non-academic clinicians.  This proposal represents the first HF-focused 
analysis of PCRR. 
 
Description of the Carolinas Palliative Care Consortium 
The Carolinas Palliative Care Consortium is a collaborative partnership between 
the DCCRP and three palliative organizations: Four Seasons Hospice and Palliative 
Care, Horizons Palliative Care, and Forsyth Medical Center. The DCCRP serves as the 
administrative and research hub of all Consortium activity, and is headed by Amy 
Abernethy, MD. Born from a recognized paucity of rigorous quality improvement 
initiatives within the hospice and palliative care community,7 the Consortium presents a 
unique vehicle through which research may be conducted. The three clinical partner 
sites are briefly described here; however, a more through description of the Consortium 
may be found in a 2010 article by Bull and colleagues.8 The first clinical partner site, 
Four Seasons Hospice and Palliative Care, is a community-based hospice and palliative 
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care organization, based in Hendersonville, NC. Four Seasons has earned an 
international reputation, having been a pioneer in the field of community-based palliative 
care. They provide care across a variety of settings, including patient homes, 21 nursing 
homes, 30 assisted living facilities, and their own 19-bed inpatient facility. Second, 
Horizons Palliative Care of Raleigh, NC, another community-based palliative care 
organization, similarly serves patients in a various settings across five counties. The last 
contributor is the inpatient palliative care unit of Forsyth Medical Center of Winston-
Salem, NC. As it is a hospital-based unit, patients from Forsyth may or may not be 
different from other patients in the PCRR.   
 
Subjects 
As of January 01, 2012, the PCRR contained data for 6,019 patients spanning a 
total of 19,668 visits. Of these records, 4,981 patients were listed to have a primary 
diagnosis other than HF or cancer, and as such, were excluded from this study. Further, 
I excluded data from the two HF patient and five cancer patients seen at the Horizons 
Palliative Care site. A cluster so small posed methodological challenges in terms of 
controlling for institution-level effects.    
The study cohort for Aim 2 comprised HF and cancer patients contained in the 
PCRR. Heart failure patients were identified using the following International 
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic 
codes: 428.xx (heart failure); 429.3 (cardiomegaly); 402.01 (malignant hypertensive 
heart disease with heart failure); 402.11 (benign hypertensive heart disease with heart 
failure); 402.91 (unspecified hypertensive heart disease with heart failure); and, 425.xx 
(cardiomyopathy).9 For the sake of clarity, this cohort hereinafter will be referred to as 
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the “heart failure” (HF) cohort, despite its multifactorial composition. The “cancer” cohort 
was defined as all patients carrying an ICD-9-CM primary diagnosis code within the 
range 140-239.9. As previously mentioned, patients from Horizons Palliative Care were 
excluded.  
 
Measures 
The key dependent variables in Aim 2 were: (1) number of unresolved 
symptoms; (2) number of treatment care gaps; (3) performance status; and (4) palliative 
care patient health status (PC-PHS), a composite indicator of adequate symptom control 
and QOL.  I defined an “unresolved symptom” as a patient (or proxy) reported severity 
rating of “moderate” or “severe” for each of the 11 symptoms captured in the PCRR; 
counts could range from 0-11. My use of the term “unresolved” signifies that symptoms 
persist at the time of first palliative care consultation – likely a reflection of the care 
received prior to palliative care referral. A “treatment gap” was defined as the lack of a 
documented intervention for a symptom rated as  “moderate” or “severe.” As 
interventions were documented for only four symptoms (pain, dyspnea, constipation, 
depression) treatment gap counts could range from 0-4. All dependent variables were 
measured at the patient level.  
Performance status was assessed using the Palliative Performance Scale (PPS), 
version 2.010,  a modification of the Karnofsky Performance Scale that has been well-
validated in palliative care patients.11  The PPS uses an 11-category ordinal scale from 
0-100% in 10-percentage point increments, with higher scores indicating better 
functioning.  As others have previously done, 12,13 I transformed PPS into a 3-category 
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ordinal variable (low performance status: 0-30%; medium performance status: 40-60%; 
high performance status: 70-100%) for clinical relevance and interpretability. 
Finally, I created PC-PHS, a composite indicator of symptom control and quality 
of life that summarized symptom management and quality of life outcomes. Originally, 
this variable was conceptualized as a scaled composite of three factors that are relevant 
to patients with advanced illness: fair/good QOL, adequate pain control, and adequate 
dyspnea control. For symptom management, I focused on pain control and dyspnea, 
which are relevant to patients with advanced HF and cancer14,15 and are often targets of 
palliative care interventions. Providers asked patients about both their current and 
maximal tolerable level of each symptom.  If current symptoms were less than the 
maximum tolerable level, or if the patient reported no current symptom, I considered that 
patient to have adequate control. QOL was assessed by providers using a single item 
measured on a 3-category ordinal scale (i.e., “poor,” “fair,” “good”); this was derived from 
the McGill QOL Questionnaire Single Item Scale: “Considering all parts of my life- 
physical, emotional, social, spiritual, and financial – my quality of life in the past two days 
was…”16 The original McGill item is scored on a 7-point scale, ranging from “very bad” to 
“excellent.” However, it is highly unlikely that in practice, this question is asked of 
Consortium patients exactly as phrased in the McGill validation studies. As such, QOL in 
this dissertation was analyzed and interpreted with caution, given that we cannot be 
confident regarding its psychometric properties. Given the small proportion of patients 
who reported “good” QOL (5%), we created a binary measure (i.e., “poor” vs. “fair/good” 
QOL). The resulting PC-PHS variable is a binary indicator that takes the value of 1 if all 
three conditions were met (i.e., controlled pain, controlled dyspnea, and fair/good QOL), 
and 0 otherwise. Presence of the PC-PHS outcome suggests better overall health, as it 
indicates adequate pain and dyspnea control, and fair/good QOL. We performed 
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sensitivity analyses using various permutations of the composite PC-PHS variable (i.e., 
1-2 vs. 3 outcomes). A graphical description of the PC-PHS variable used for Aim 2 is 
offered in Figure 3.2.  
Recognizing concerns that a dichotomous indicator of QOL might be limited in its 
sensitivity, I explored the possibility of combining QOL and performance status to 
provide a more comprehensive and clinically meaningful measure. However, since I 
found final-visit QOL and PPS to be weakly correlated (Spearman’s rho = 0.26, p ≤ 
0.001), it was inappropriate to proceed with this transformation. Instead, I chose to 
analyze QOL and PPS separately.   
 
Analysis 
Aim 2 sought to answer three broad questions: 1) Is the prevalence of 
unresolved symptoms and treatment gaps similar between HF and cancer patients; 2) 
Do HF patients report similar QOL and exhibit similar PPS at the time of admission to 
palliative care; and 3) Are HF patients as likely as cancer patients to experience better 
health status at the time of palliative care admission?  
After calculating unresolved symptoms and treatment gaps as previously 
described, I used descriptive statistics to compare their prevalence within both the HF 
and cancer cohorts. To address hypothesis 2b1, which states that HF patients will 
present with more unresolved symptoms and treatment gaps than cancer patients, I first 
used Student’s t-tests between cohorts. Next, Poisson regression was used to model the 
effect of primary diagnosis on the count of care gaps, while adjusting for relevant 
covariates.17 I chose Poisson regression given the count nature of the unresolved 
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symptom and treatment gap index variables. Therefore, hypothesis 2b1 entailed two 
separate Poisson regressions for each of the indices (Eq. H2b1).  
 
Count(unresolved symptoms or treatment gaps) = f(β0 + β1HF + β2 Age + β3Male 
+ β4 Non-white + β5PPS + β6ProxyRespondent + β7CareSetting + ε) 
         Eq. H2b1 
To test hypothesis 2c1 regarding the effect of HF on PC-PHS, I constructed the 
following modified Poisson regression, with PC-PHS operationalized as a dichotomous 
variable (Eq. H2c1). Due to the binary nature of these outcomes, modified Poisson 
regressions with robust sandwich errors was used to estimate risk ratios.18 Robust 
standard errors were calculated to avoid bias from incorrectly specified variance.19 I 
chose risk ratios over odds ratios for two reasons. First, although odds ratios derived 
from logistic regression are commonly reported in the health services literature, odds 
ratios are known to overestimate relative risk when outcomes are non-rare (>10%).20 
Second, confusion over the appropriate interpretation of odds ratios is common, 
whereas risk ratios may be more intuitive to a wider audience.  
 
Pr(PC-PHS)= f(β0 + β1HF + β2 Age + β3Male + β4 Non-white + 
β5ProxyRespondent + β6CareSetting + ε) 
         Eq. H2c1 
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Performance status was modeled as 3-category ordinal variable regression (low, 
medium, high) using a generalized ordered logistic regression (Eq. H2d1).21 This 
modification is in line with prior analyses of the PPS operationalized in this fashion.12  
 
PPS = f(β0 + β1HF + β2 Age + β3Male + β4 Non-white  + β5ProxyRespondent + 
β6CareSetting + ε) 
         Eq. H2d1 
 
 
Aim 3: Assessment the process-outcome link in HF patients receiving community-
based palliative care  
Subjects  
Aim 3 assessed the association between quality indicator adherence at first 
palliative care consultation and outcomes assessed at final palliative care consultation. 
As such, the analytic sample of Aim 3 required that all patients were deceased at the 
time of analysis, and were a subset of the dataset in Aim 2 , described previously. Given 
the patient population, it is reasonable to speculate that more patients were indeed 
deceased, and that dates of death had not been not been recorded in the database. As 
such, I manually reviewed all HF patient records in the PCRR, and confirmed vital status 
using the Social Security Death Index, accessed via www.ancestry.com.22  
An additional inclusion criterion for Aim 3 was that patients have at least two 
palliative care consultations documented in the PCRR. Patients seen only once may 
differ from other palliative care patients on a variety of dimensions, including baseline 
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illness severity, poor prognosis, and access to care issues. As I was limited in my ability 
to control for such potential sources of selection bias, I chose to exclude such patients 
from this analysis. Imposing these restrictions, I was left with an analytic sample of 85 
HF patients.    
 
Measures 
The overarching goal of Aim 3 was to identify quality indicators that are 
independently associated with patient-centered outcomes at patients’ final palliative care 
consultations. As in Aim 2, I used the PC-PHS variable as the outcome of choice; 
however, in Aim 3, PC-PHS equaled 1 if at least two of the three component outcomes 
(i.e., fair/good QOL, adequately controlled pain, adequately controlled dyspnea) were 
true, whereas in Aim 2, all three outcomes had to be present for PC-PHS to equal 1. 
These justifications were based on the distribution of outcomes within each analytic 
sample. A graphical description of the PC-PHS variable used in Aim 3 is offered in 
Figure 3.3.  
The key independent variables of Aim 3 were dichotomous indicators of quality 
indicator satisfaction. As described previously, a central component of Aim 1 was the 
quality indicator ranking exercise, which resulted in five indicators that were ranked as 
clinically important by provider interviewees.  These variables were constructed by 
reviewing clinical details contained in PCRR, and captured processes of care related to 
patients’ first palliative care consultations. Given the mixed-methods approach of this 
dissertation, Aim 3 analyses depended on Aim 1, and followed in sequence.  
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Given the limited and fixed sample size, I constructed a patient-level adjustment 
score to reduce the dimensionality of regression models; this technique has been 
previously applied to similar studies of healthcare quality assessment.23,24 Variables in 
the adjustment score were: (1) age at time of first palliative care consultation; (2) gender; 
(3) race; (4) patient versus proxy report; (5) care setting (i.e., hospital inpatient versus 
patient’s home); and, (6) total number of palliative care consultations recorded in the 
PCRR. I attempted to include performance status (as a proxy for disease status and 
prognosis) in the adjustment model; however, it was excluded due to multicollinearity 
with number of palliative care consultations.  
 
Analysis  
Described here is the regression modeling used to assess the palliative care 
process-outcome link in a cohort of HF patients receiving community-based palliative 
care services. In a recent study of stroke care quality that is conceptually similar to the 
Aim 3, Bravata and colleagues used a 3-step process to conduct their analyses.23 First, 
they calculated descriptive statistics to describe the prevalence of quality indicator 
adherence in their population. Next, they modeled each process indicator in separate 
regressions to yield unadjusted measures of association. Finally, they created a model 
that adjusted for all of their quality indicators of interest, as well as other covariates.  Aim 
3 of this dissertation followed a similar analytic process.  
As with several Aim 2 regressions, due to the binary nature of PC-PHS, modified 
Poisson regression with robust standard errors was used.18 Robust standard errors were 
calculated to avoid bias from incorrectly specified variance.19 Risk ratios were chosen for 
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the same reasons as in Aim 2. Additionally, risk ratios are the proper measure of 
association given that Aim 3 was a cohort study.  
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FIGURES AND TABLES 
Table 3.1. Summary of analyses in Kavalieratos dissertation 
	    
Research Questions (RQ) & Hypotheses Analytic Methods 
AIM 1: TO IDENTIFY POTENTIAL PHYSICIAN BARRIERS TO REFERRING 
PATIENTS WITH HF FOR PALLIATIVE CARE 
RQ 1a: What are the knowledge, attitudes, and experiences that 
cardiology, primary care, and palliative care physician and non-
physician providers have regarding heart failure-specific palliative 
care? 
 
 
Semi-structured 
interviews; 
template analysis 
 
 
RQ 1b: What barriers potentially impede greater referral of HF 
patients for palliative care? 
RQ 1c: What are the attitudes of cardiology, primary care, and 
palliative care physician and non-physician providers regarding the 
relevance and utility of proposed palliative care quality metrics to 
advanced HF care?  
AIM 2: TO ASSESS & COMPARE UNRESOLVED SYMPTOMS AND TREATMENT 
GAPS, AND PATIENT-CENTERED OUTCOMES BETWEEN HF AND CANCER 
PATIENTS RECEIVING PALLIATIVE CARE 
RQ 2a:  What are the unresolved symptom and treatment gaps 
experienced by HF patients at their first palliative care consultation? 
Descriptive 
statistics 
RQ 2b: Is a primary diagnosis of HF associated with a greater prevalence of unresolved 
symptoms and treatment gaps at first palliative care consultation, relative to cancer? 
H2b1 HF patients will present with a greater number of 
unresolved symptoms and treatment gaps at their first 
palliative care consultation, than will cancer patients 
Poisson 
regression 
RQ 2c:  Does palliative care patient health status differ between cancer and HF patients 
at the time of first palliative care consultation? 
H2c1 There will be no statistically significant difference in the 
proportion of HF and cancer patients with fair/good QOL, 
adequate pain control, and adequate dyspnea control at the 
time of their first palliative care consultation.  
Modified Poisson 
regression 
RQ 2d:   Does performance status differ between cancer and HF patients at the time of 
first palliative care consultation? 
H2d1 Primary disease (HF vs. cancer) will not be significantly 
associated with performance status at the time of first 
palliative care consultation  
Generalized 
ordered logistic 
regression 
AIM 3: TO ASSESS THE ASSOCIATION BETWEEN PALLIATIVE CARE QUALITY 
INDICATORS AND PATIENT-CENTERED OUTCOMES 
RQ 3a: What is the profile of outcomes experienced by HF and 
cancer patients at their final palliative care consultation? 
Descriptive 
statistics 
RQ 3b: What is the association between the satisfaction of palliative care quality 
indicators at first palliative care consult, to palliative care patient health status (PC-PHS) 
assessed at final palliative care consult? 
H3b1 Adherence to palliative care quality indicators at first 
palliative care consultation will be positively associated PC-
PHS at final palliative care visit 
Modified Poisson 
regression 
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Table 3.2. Recruitment matrix for Study 1 interviews 
 
 Cardiology Primary Care Palliative Care 
Academic Affiliation 2 MD/DO;  
1 NP/PA 
2 MD/DO;  
1 NP/PA 
2 MD/DO;  
1 NP/PA 
Non-Academic Affiliation 2 MD/DO;  
1 NP/PA 
2 MD/DO;  
1 NP/PA 
2 MD/DO;  
1 NP/PA 
Abbreviations: MD, Doctor of Medicine; DO, Doctor of Osteopathy; NP, Nurse 
Practitioner; PA, Physician Assistant.  	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Figure 3.1. Interview guide used in Aim 1 
# Question and associated probes 
0 [All] What drew you into [cardiology/primary care/palliative care] as a specialty? 
1 [All] Using the patient case before you, could you please walk me through your 
main concerns regarding how to best manage his care?  
• What is your approximation of this patient’s life expectancy? 
2 [All] What needs do HF patients possess, and how do you try to address them? 
• How successful do you think you are in managing these needs? 
• Are there any specific needs/concerns that you feel you might not be addressing 
well? 
• [Cardiology/primary care] Who is typically involved in the care of HF patients? 
3 [Cardiology/primary care] How do you approach discussions with patients about 
prognosis? What about the balance between a focus on symptom management and 
quality of life improvement vs. increasing survival? 
4 [Cardiology/primary care] What is your familiarity with palliative care?  How do you 
define it? 
[Palliative care] How prepared do you feel to care for HF patients, relative to cancer 
patients? Is there anything that you think needs to change to improve your ability to 
care for HF patients? 
•  [Cardiology/primary care] Please describe to me your familiarity with HF-
specific palliative care? 
5 [All] What, in your opinion, makes a HF patient eligible for palliative care?  
• What, in your opinion, would need to happen to make this patient eligible for 
palliative care? 
6 [All] What opportunities exist for other clinical specialties to assist in the 
management of HF patients? 
• Should palliative care could be incorporated into HF care? If yes, how so? 
• Can palliative care be helpful to the management of HF patients, and if so, how? 
[Cardiology/primary care] What are your thoughts regarding collaborating with a 
palliative care service in managing HF patients? 
7 [Cardiology/primary care] Do you know whether palliative care services exist in your 
area? If so, have you ever referred a HF patient for palliative care?  
[Palliative care] Have you ever cared for a patient with HF who needed symptom 
relief and palliation? 
• [All] If yes, can you please describe the experience? 
• [Cardiology/primary care] If not, can you please describe your reasons for not 
doing so? 
• [Palliative care] If not, why do you think that you haven’t yet been referred a HF 
patient? 
8 [All] What are some of the barriers that you believe might impede the uptake of HF-
specific palliative care? Physician-level barriers? System- or policy-level barriers? 
Patient- or family-level barriers? 
• How might these barriers be overcome? 
9 [All] If you suspect that a HF patient can benefit from palliative or hospice care, who 
do you believe is responsible for discussing this with the patient: Primary care, 
cardiology, or a palliative care specialist? A physician or a nurse? 
10 [All] Are there any points regarding symptom management for HF patients that you 
think we haven’t covered? 
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Table 3.3. Distribution of HF and cancer patients within the Carolinas Palliative 
Care Consortium  
Provider Care Setting Heart Failure Cancer Total 
Forsyth Medical Center Hospital inpatient only 84 367 451 
Four Seasons Mixed 250 330 580 
Horizons Palliative Care a Mixed 2 5 7 
Total 336 702 1038 
Note: a: excluded from dissertation analyses.  
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Figure 3.2. Composition of the Palliative Care – Patient Health Status (PC-PHS) 
variable used in Aim 2 analyses 
 
 39 
Figure 3.3. Composition of the Palliative Care – Patient Health Status (PC-PHS) 
variable used in Aim 3 analyses 
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CHAPTER 4: PROVIDER-RELATED BARRIERS IMPEDING HEART FAILURE 
PALLIATIVE CARE REFERRAL 
 
INTRODUCTION 
Heart failure (HF) is a highly prevalent chronic disease characterized by high 
physical and psychosocial burdens that dramatically impair patients’ quality of life and 
performance status.1-3 Approximately 80% of Medicare beneficiaries with HF are 
hospitalized within the last 6 months of life, a trend that has increased over time.4 
Current therapies for HF relieve symptoms and prolong survival, but are not curative.5  
Palliative care is a multidisciplinary intervention that focuses on optimizing quality 
of life for patients and families affected by serious illness, independent of prognosis.6 
Important components of palliative care intervention include: expert identification and 
management of pain and other symptoms; psychological, spiritual, and logistical support; 
assistance with treatment decision-making and setting care goals; and, complex care 
coordination.7 Palliative care utilization has been suggested to improve survival,8 quality 
of life,8,9 symptom burden,10 healthcare expenditures,7 hospice transitions,7 and 
caregiver outcomes.11 Notably, palliative care is distinct from hospice care, which is 
intended for patients with a maximum expected life expectancy of six months. Non-
hospice palliative care may be initiated at any point in the disease trajectory and may be 
administered in conjunction with curative or life-prolonging treatments. (Figure 4.1)  
The American College of Cardiology and the American Heart Association 
recommend that palliative and/or hospice care be considered with advanced HF 
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patients12 while mounting attention elsewhere calls for palliative care integration across 
the HF trajectory.5,13-18 However, despite striking similarities regarding symptom 
burden3,19-21 and prognosis with advanced cancer patients, HF patients use supportive 
services at lower rates. In 2008, cancer was the leading diagnosis among hospice 
enrollees (38.3%), whereas HF ranked 3rd (11.7%).22  Recent U.S. incidence statistics 
estimate 1.6 million patients to be diagnosed with cancer in 2012,23 and more than 
550,000 HF diagnoses in 2008.24 Importantly, recent research suggests that 
implementation of the aforementioned guidelines may be suboptimal. In one study, more 
than half of cardiologists surveyed would not discuss palliative care with elderly patients 
with advanced HF.25 Coupled with extremely low public knowledge of palliative care,26 
this barrier may contribute to its underutilization among patients with HF.  Past research 
on palliative care referral barriers in HF have been conducted in the U.K. and 
Australia.27-30 Recognizing differences in healthcare delivery systems, reimbursement 
policies, and culture, we conducted a qualitative study with diverse American providers 
to understand barriers to referring patients with advanced HF to palliative care. Among 
primary care, cardiology, and palliative medicine providers, what are the barriers related 
to palliative care referral for patients with HF? 
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METHODS 
Design 
We conducted semi-structured interviews both to allow flexibility in exploring 
topics and for subjects’ convenience. The University of North Carolina at Chapel Hill 
Institutional Review Board approved this study. Participants provided informed consent 
electronically.  
 
Sample and recruitment 
We used purposeful, stratified sampling to recruit primary care, cardiology, and 
palliative care physicians and non-physician providers from diverse practice settings 
(i.e., academic/non-academic, urban/rural).31 We chose these providers because of their 
prominent role in decision-making regarding palliative care for patients with advanced 
systolic HF.  We used the following eligibility criteria: a) physician, nurse practitioner, or 
physician assistant; b) currently in practice in North Carolina; and, c) cared for ≥3 HF 
patients in the preceding six months. We offered a $50 honorarium and a summary of 
our findings.  
   
Data collection 
One author (DK) conducted all interviews, either in person or by telephone, 
between December 2011 and May 2012. Based upon a literature review regarding care 
transitions in HF and discussions with three experts, we developed an interview guide 
(Table 4.1) containing ten questions in four domains: (1) needs of HF patients; (2) 
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knowledge and perceptions of palliative care; (3) indications for, and optimal timing of, 
palliative care referral in HF; and, (4) barriers to palliative care referral in HF. We 
designed probes for “iterative questioning” to explore participants’ responses to 
questions to increase validity.32  
Prior to the interview, we asked participants to review a vignette of a hypothetical 
patient with advanced HF, typical comorbidities, and unaddressed palliative needs 
(Table 4.2). Such elicitation methods are helpful when exploring values and 
perceptions.33  Interviews were audiotaped and transcribed verbatim. Demographic 
information was collected in a pre-interview internet survey. 
 
Data analysis  
We analyzed data using template analysis, a qualitative approach that combines 
content analysis and grounded theory.34 Template analysis allows flexibility to integrate a 
priori assumptions and hypotheses for a hybrid inductive/deductive analytic process. 
Data analysis was performed in an iterative fashion, with the initial codebook informed 
by an extensive literature review. Two authors (DK, EMM) independently read and 
coded a random 50% sample of transcripts in three iterative stages. After each round of 
coding, consensus meetings were held to discuss and arbitrate discrepancies. DK coded 
all remaining transcripts, which were reviewed and verified by EMM.  Using the constant 
comparative technique, text units were compared with previously-coded data to ensure 
the stability and relevance of emergent themes.35 We used NVivo936 to code and query 
transcripts. Matrix and compound queries were performed to further explore our data. 
We applied eight techniques (Table 4.3) to improve the trustworthiness of our findings 
across four domains: 1) credibility; 2) transferability; 3) dependability; and, 4) 
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confirmability.37 Themes and illustrative quotes identified were agreed upon by all 
authors.   
 
RESULTS  
We conducted 18 interviews, generating 188 pages of data. The median 
interview lasted 37 minutes (range: 25-51 minutes). Within each of our three specialty 
areas of interest, we recruited four physicians and two non-physician providers (Table 
4.4). Generally, non-physician providers’ comments resembled the comments of 
physicians within their respective specialties; thus, we present findings by specialty, and 
not by provider type. We inductively discovered a natural structure to our themes in a 
“what, when, why, who, where, and how” framework (Figure 4.2).  
 
“What”: Lack of functional knowledge regarding palliative care  
Although all participants reported that they could define palliative care, further 
probing revealed that their conception varied among the providers and also varied from 
the standard definition of palliative care from the literature. Specifically, nearly all primary 
care and cardiology respondents lacked clarity that palliative care is not prognosis-
dependent and may be administered concurrently with aggressive or life-sustaining 
therapy. As opposed to hospice, participants in our sample failed to recognize palliative 
care as a tangible clinical service.  For example, one primary care physician said: 
“Palliative care is a philosophy. Hospice is a treatment approach complete with billables, 
and payers, and all that crap, within that treatment philosophy.” When we asked 
participants to describe eligibility and appropriateness criteria for palliative care (for 
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which there are none, aside from patient need), cardiology and primary care participants 
generally used the terms interchangeably until explicitly prompted for clarification.  
  
Interviewer:  So in your opinion, what makes a HF patient eligible for 
palliative care? 
Cardiologist:  Eligible?  Well, eligibility is not my decision.  I mean, that’s a 
legislative decision….  
Interviewer:  And, so in your mind, is there a distinction between palliative 
care and hospice care? 
Cardiologist:  Between palliative and hospice care?  No.  There’s not.  Not 
in my mind.  Is there?  
 
Incorrectly believing that palliative care mandates the suspension of aggressive 
or life-prolonging therapies, participants claimed that patient goals determine eligibility:  
 
…If the patient wants to focus on symptoms and is willing to accept the 
sort of basics, and that’s significantly and far away the primary goal of 
care for the patient, then the patient’s eligible for palliative care.  (Primary 
care physician)  
 
A few cardiology and primary care providers recognized differences between 
palliative care and hospice. For example, as one primary care physician stated:  
 
… I think I’m reasonably familiar [with palliative care], but I also think that 
to me, it’s become somewhat of a confusing term.  I view palliative care 
as trying to understand the patient’s symptoms and values and wishes, 
and really trying to help them maximize their quality of life and reduction 
of symptoms.  And I see it as something distinct from, say, hospice care.  
I worry that sometimes we confuse palliative care, meaning it has to equal 
end of life care, and I prefer to view palliative care as clear management 
of symptoms and emphasis of the patient’s quality of life in decision-
making.  
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We asked participants whether they had ever collaborated with a palliative care 
service. Most non-palliative care participants had no experience with a formal palliative 
care provider/team. Participants frequently acknowledged not knowing how to access 
palliative care support within their own institutions, such as this primary care physician 
from a large academic medical center: 
 
I don’t even know where they are or where they exist, or even really what 
they do….I wouldn’t even know where to start to try and get in touch with 
someone.  
 
“When”: Appropriate timing for palliative care referral  
Most participants conceptualized referral in terms of “triggers,” including 
physiological findings (e.g., symptom presence), disease status (e.g., functional decline), 
or events (e.g., ventricular assist device implantation).  Among primary and palliative 
care providers, repeated hospitalization over a short interval (e.g., 3 in 6 months) was 
perceived to indicate that palliative care might be appropriate. However, cardiology 
participants frequently discussed the “point at which you are unable to do more” as 
another trigger:  
 
… I think that the trigger to get [the palliative care service] involved was 
knowing that my patient was dying and that I didn’t have other medical 
options for them.  Meaning that they weren’t candidates for advanced 
therapies and that there was nothing else I could do to alter the natural 
history of the disease and that there was a clear need for someone skilled 
in palliative care to help with that patient and not only help with that 
patient but help with that patient’s family… (Cardiologist)  
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However, some participants reflected on the difficulty of recognizing and acting 
upon triggers.  
 
…I think the main challenge is both for the cardiologist and for the patient, 
recognizing those prognostic signs that say this is an individual who is 
moving into the last phase of their disease. There’s so much experience 
with successful management of exacerbations, of systolic congestive HF, 
that it’s hard for both the patient and the doctor to say, ‘Wait a minute. 
The pattern is changing. There’s (sic) more exacerbations. They are more 
often. They’re more severe. It’s more difficult to get this person back from 
the edge.’ So just recognizing that I think is difficult. (Palliative care 
physician) 
 
Participants commonly mentioned the insistence on life-prolonging treatments, 
such as inotrope therapy, as a barrier to palliative care referral. One palliative care 
physician stated: 
 
I think that [cardiologists] are not only procedure driven but intervention 
driven in that . . . I think they have a hard time seeing an endpoint with it, 
in the same way that oncologists have a difficult time really seeing when 
their treatments just aren’t working anymore.   
 
The unpredictable trajectory of HF was a frequently-cited barrier to palliative 
care, especially when participants believed that palliative care eligibility or 
reimbursement were prognosis-dependent (as with hospice).  
 
…I think what we do, at least what I do, from a palliative care standpoint 
is I think, ‘Oh, patient has likely less than six months of life, and an official 
team involved would be really helpful.’  As opposed to someone who has 
longer than that, a palliative care team might be helpful, but it might not 
yet be appropriate because we’re not exactly sure how long they have… 
(Cardiologist)  
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Unprompted, our palliative care participants lamented that late referrals limit the 
potential benefit to patients:  
 
In general, I feel like I’m consulted much later than I would prefer to 
be….Usually it’s someone that’s in pretty severe distress from symptoms 
is when I’m consulted. And I feel like when I’ve had a more close working 
relationship with a group of hospitalists, then that makes them much more 
comfortable sort of consulting me early with a symptom-management 
focus, and so I’ve sort of seen my practice change since I’ve been in this 
setting for over a year now.  I feel like initially, …I was called for hospice 
evaluation for appropriateness...  Now, I feel like I’m getting consulted 
much more early with just a symptom sort of focus.  And I sort of begin 
that education process with them. You know, unfortunately or fortunately, 
however you see it, as a patient is readmitted over time, myself or my 
colleagues now have multiple times and we’re able to sort of increase the 
education and improve on their symptom burden and kind of relieve that a 
little bit over time.  (Palliative care physician)  
 
“Why”: Perceptions of palliative care in HF 
All participants endorsed palliative care in HF, to varying degrees. They believed 
that palliative care providers are experts regarding: symptom management; care 
coordination; and advance care planning (e.g., facilitating difficult discussions regarding 
prognosis). Many appreciated its focus on quality of life:  
 
…I think a more formal collaboration with the palliative care service team 
would be ideal so that we’re not using them haphazardly “oh yeah when 
we think about it,” but I think that we have that in our thought process.  
We’re trained as physicians and want to make everyone live forever, and 
we advocate very strongly for our individual patients during these 
meetings, but to have a voice from the palliative care service team where 
we don’t forget to focus on quality of life as much as survival would be I 
think ideal for the patient population that we see.… [W]e’re so focused on 
altering the natural history of their heart disease rather than necessarily 
looking at the whole patient. (Cardiologist)  
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Participants also discussed how sociocultural attitudes regarding mortality 
influence provider behavior. Again, we noted a tendency for participants to allude to 
hospice when discussing the role of palliative care in HF.  
 
It’s almost a cultural-level barrier.  You know, if there’s more than a trivial 
possibility you might live three or four years, then why not go for it?  I 
think it’s the way that many of us were raised, both as patients and 
physicians….  [C]ardiologists often go into cardiology ‘cause they want to 
save lives with their stents and the like, and so that may be a barrier…. 
[There is a] cultural bias against adopting palliative care unless you ‘know 
you’re going to die.’ (Primary care physician) 
 
 Participants commonly drew contrasts between HF and cancer. Unlike the cure-
oriented goal of oncology, participants believed that the reality of HF as a progressive, 
incurable disease poses challenges to conceptualizing how palliative care differs from 
standard HF management: “…[A]ll medical therapy for HF is really to relieve their 
symptoms.  And so, in a sense, to me, it all feels like palliative care.” (Primary care 
physician)  
A cardiologist participant did not feel as strongly, but did maintain the notion that 
a sizable portion of his work in treating HF is palliative in nature:  
Cardiologist: Well, unfortunately I think a lot of what we do as HF doctors 
involves the idea of palliative care…   
 
Interviewer: When you say that most of what you do in HF care is of a 
palliative nature, can you describe how you come to that determination? 
 
Cardiologist: I guess I shouldn’t say most of what I do. I guess I should 
say a fair portion of what I do…. I think that it’s important to be 
candid…that for Class III or IV patients, medical therapy over the course 
of the past twenty years really hasn’t changed their life expectancy at all.  
And so there are no magic pills that we can pull out that will help this 
patient to live longer.  And so I think given that, I think it’s important to 
focus your discussion on how they want to live the life that they have 
remaining.  
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“Who”: Inter-provider relationships and responsibilities 
To gain or increase acceptance in contexts of limited palliative care familiarity, 
participants thought that palliative care must demonstrate and market its benefit to 
patients and providers. Trust and rapport were identified as key facilitators to palliative 
care referral, particularly when knowledge of palliative care is limited. Palliative care 
participants discussed how networking and peer education have resulted in greater and 
earlier referrals, by “winning over” previously skeptical colleagues:  
  
…I think a lot of people really don’t know what we do.  I did a consult not 
too long ago.  I showed up.  The doctor looked up from the desk and he 
said ‘My patient doesn’t need a morphine drip’ and I said, ‘I’m not here to 
start one.’  I said, ‘I do a whole lot more than start morphine drips, thank 
God.’  So I actually in a good-natured way, really try to do a little 
education with folks, and I think they really appreciate it. That same 
cardiologist has sent me several more consults since then…I think once 
he realized that we’re not the grim reaper service and that we’re really 
about what does the patient want, they sort of lay down their baggage. 
(Palliative care physician)  
 
“Where”: Origin of referral 
All participants, except one cardiology nurse practitioner, felt that primary care or 
cardiology providers should initiate conversations about palliative care because of their 
preexisting, ongoing relationships with patients. However, palliative care participants 
feared that such conversations might not occur due to providers’ discomfort with 
discussing palliative options or due to time constraints. One palliative care physician 
discussed what she perceived as her flexible, but overall supportive role within a care 
team:  
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I think any of those physicians can introduce the concept. Any of them. 
And I’m perfectly comfortable handling the relationship any way that the 
other physicians involved want to. They need to acknowledge that we’re 
coming. They need to say, ‘Yeah, we’re going to involve palliative care. 
We endorse the palliative care team being involved in your care.’ But I 
think it’s perfectly fine for the primary treating cardiologist to begin that 
conversation . . . to say, ‘We need to start talking about your HF being in 
its latest stages. We need to think about what our options are for how to 
give you the best quality of life under these circumstances.’ But it’s also 
perfectly fine for them to duck that conversation and say, ‘I want to pass 
the baton. I want the palliative care team to really help with that more 
difficult communication.’ It’s really just whatever works for the group of 
people involved.  
 
“How”: Provider-level strategies to increase palliative care referral  
Overwhelmingly, participants felt that the primary barrier to palliative care referral 
was lack of knowledge within the medical community. Though some participants 
commented on the value of educating patients about palliative care options, most viewed 
healthcare providers as the most logical target for intervention. Cardiology and primary 
care participants recognized the need to increase exposure to palliative care during 
graduate or postgraduate education: 
  
…[E]ducating HF physicians on the value and availability and the 
utilization of palliative care services is key.  I don’t think we get a good job 
of learning about that during our medical school or residency or fellowship 
training and if you don’t train us at that point, you can’t expect us to 
understand or know how to use them at this point…. I think many of us 
physicians struggle with even bringing up the palliative care concept with 
patients because we’re just not skilled necessarily at doing it.   
(Cardiologist)  
 
Participants from all specialties perceived the need to develop “palliative care 
basics” (e.g., symptom identification/management in serious illness, communication 
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skills regarding goals of care). Motivations for this varied across specialties. For 
example, whereas some of our cardiology participants desired to gain confidence in 
difficult communication, palliative care providers often spoke of workforce constraints:   
  
…There are still only 3,000 board-certified palliative medicine physicians 
in the US. Most of them are hospital-based or their practices are 
predominantly hospital-based. So from a practical standpoint, I think that 
has a couple of implications. One is the dominant model in the next 
several years would be to promote early inpatient consultation or inpatient 
assistance with management, maybe through identifying mutually agreed 
upon triggers for referrals with a cardiology service. And then I think the 
second element is to ramp up the level of palliative care expertise that 
cardiologists, particularly those that focus on HF, have to exercise in their 
own practice so that it’s not purely dependent on consultative services… 
(Palliative care physician)  
 
Lastly, participants discussed various practical strategies by which to encourage 
palliative care referral. One primary care nurse practitioner noted her desire for better 
integration of palliative care in existing clinical decision support systems: 
 
…[Palliative care referral] relies on me asking for it when it probably 
should be more automated.  It’s like if someone has a big tumor on a CT 
scan, it’s pretty quick how they get into an oncologist or get in for a biopsy 
but if it’s got a really clear indicator for worsening trajectory, they don’t 
automatically get these services.  So I think that’s where the system is 
kind of impeding people getting into palliative care.” 	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DISCUSSION 
To our knowledge, this study is the first to explore provider-related barriers to 
palliative care referral for advanced HF patients among U.S. providers, particularly 
clinical specialties frequently caring for these patients.  We found limited knowledge 
related to: what palliative care is (especially how it differs from hospice); what it offers 
patients, families, and providers; when it is indicated; and, how to access it.  
One barrier is confusion about the term “palliative care” itself.  Through iterative 
probing, all providers claimed to be familiar with non-hospice palliative care; however, 
we often heard phrases such as “comfort care” or “just the basics,” hinting that they 
equated non-hospice and hospice palliative care.  Notably, providers often reported 
criteria for hospice  (i.e., less than six months expected survival and desire to suspend 
life-sustaining treatments) as those criteria for non-hospice palliative care. Though 
alarming, this finding has been documented elsewhere.30,38,39 However, because 
providers almost unanimously reported using trigger events (e.g., symptom intractability 
or patients becoming too complex to be managed by primary care or cardiology) to 
initiate palliative care, this misconception may encourage late (if any) palliative care 
referrals.38 Our findings echo previous work suggesting that providers choose to delay 
conversations regarding prognosis or end-of-life decision-making.40 These provider 
misperceptions, along with a 2011 public opinion poll in which 70% of adult respondents 
claimed to be “not at all knowledgeable” regarding palliative care,26 may partially explain 
its underutilization in HF. In addition, we interviewed providers across North Carolina, 
including in regions without palliative care services, which may inherently limit 
knowledge of and familiarity with specialist palliative care services; however, the majority 
of providers interviewed were within close proximity of palliative care services (both 
inpatient and outpatient).  
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Participants frequently reported the unpredictable nature of HF as a barrier to 
palliative care referral.27,29,30 Clearly reflecting a hospice-oriented mindset, this finding 
highlights the risks of using rigid, standardized heuristics when caring for seriously ill 
persons, 29 thus adding to the longstanding discussion regarding the appropriateness of 
the Medicare hospice benefit model,41 particularly for diseases with unpredictable 
trajectories.42 Crisp demarcations between curative and palliative treatment modalities 
reflect a false dichotomy that defers a focus on quality of life improvement until disease 
futility has been established.17  
Prior qualitative research with physicians27-29 and nurses30, performed in the U.K. 
and Australia, suggests a mixture of professional, organizational, and cognitive factors 
impeding palliative care referral for HF patients, including concerns that patients might 
be “stolen” by palliative care providers.27 In contrast, all non-palliative providers we 
interviewed explicitly expressed interest in exploring how to collaborate with palliative 
care providers. The frailty of patients with chronic, debilitating illnesses such as HF 
warrants exploration of methods to increase access to palliative services, such as 
outpatient and community-based palliative care programs.43-45 
As suggested by others,28,46 our findings support that the role of specialist 
palliative care has yet to be defined in cardiology, as it has in oncology. Indeed, though 
our inherent assumption is that specialist palliative care improves HF patient outcomes 
(as has been shown in lung cancer8), data do not currently exist to support this claim. 
Furthermore, no research exists to delineate the role of specialist palliative care 
providers versus cardiologists versus primary care providers in providing palliative 
services to HF patients. Nevertheless, our participants saw inherent value in the 
expertise of palliative care providers. Although some expressed difficulty understanding 
how formal palliative care services would differ from the ultimately palliative treatments 
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of standard HF management, others viewed palliative care as particularly attractive for 
HF care, owing to the complex treatment decisions such patients face. Palliative care 
may be especially beneficial during the early stages of disease, as a way to elicit patient 
preferences and discuss understanding of likely prognosis.6 Moreover, because HF 
patients commonly experience multi-morbidity and receive care from numerous 
providers palliative care services can help reduce care fragmentation and suboptimal 
inter-provider communication patterns.27,47 Such coordination is especially important as 
American healthcare delivery moves towards patient-centered medical homes. 
Participants expressed interest in educational interventions regarding palliative 
care, which is consistent with previous work.17,48 Participants reported that efforts must 
originate from the field of palliative care, a view echoed by one palliative care physician:  
“We must reach out and give [cardiology and primary care providers] the language [of 
palliative care].” Medical school curricula should both educate medical providers about 
palliative care and hospice services, as well as train providers to feel confident in: 
navigating difficult or uncomfortable conversations regarding prognosis and life-
prolonging treatments (e.g., device deactivation); identifying and managing symptoms of 
advanced HF; and, recognizing when and how to maximize the utility of specialist 
palliative care services to improve HF patients’ quality of life. Currently, palliative care 
providers will need to correct misconceptions regarding their discipline, services, and 
role in managing seriously ill patients.  
This study has several limitations. First, the generalizability of our conclusions 
may be limited because: (1) our respondents practice in North Carolina, which may vary 
from other regions regarding palliative practice patterns and culture; and (2) although we 
achieved relative balance between urban and rural settings (data not shown), a greater 
proportion of our sample practice in large, academic medical centers, the site of most 
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palliative care programs.49 As such, it is defensible that our work reflects a positive bias 
regarding palliative care knowledge. In other words, our participants were likely more 
familiar with palliative care than most providers. Second, although we used sound 
methodological techniques to maximize rigor and trustworthiness of our data, it is 
possible that others may have identified different themes.  Third, participants’ responses 
may have been influenced by social desirability and interviewer bias.  Finally, our study 
did not explicitly assess patient or family perspectives, which may influence the 
healthcare experiences of patients with serious illness.50  
We provide empirical data to initiate the discussion regarding provider-related 
palliative care barriers for patients with HF in the U.S. This issue is relevant to a 
generalist audience due to the prevalence of HF, and the frequency with which primary 
care providers orchestrate the care of such patients.  Our findings suggest that deficits in 
both knowledge about palliative care and providers’ comfort in discussing end-of-life 
care for a clinical condition with a difficult-to-predict course present major barriers to 
referring patients with advanced HF to palliative care. Our findings highlight the need for 
efforts to increase awareness of palliative care among the medical and lay communities. 
While establishing and promoting its role, palliative care must correct misconceptions 
that it is only appropriate for the terminally ill. Future research should seek to develop 
provider- and patient-centered interventions to reduce actionable barriers to palliative 
care uptake in HF. Additionally, efforts are needed to understand patient and family-level 
barriers to palliative care utilization amongst HF patients.   
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FIGURES AND TABLES 
Figure 4.1. Illustration of the relationship between non-hospice and hospice 
palliative care 
 
 
Abbreviations: HF, heart failure; ACC/AHA: American College of Cardiology/American 
Heart Association; NYHA: New York Heart Association 
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Table 4.1. Interview guide: domains of interest and sample questions 
 
Domain Sample Question 
Needs of heart failure 
patients 
On the whole, what needs do your heart failure patients 
possess? 
How effective do you believe that you are in managing 
your heart failure patients’ needs? 
Knowledge and 
perceptions of palliative 
care 
What is your familiarity with palliative care? How do you 
define it? 
Throughout our conversation, I’ve been using the term 
“palliative care,” and I’ve been hearing you use the term 
“hospice.” Are those interchangeable for you, or do you 
see a distinction between them? 
Can palliative care be helpful in the management of heart 
failure patients? If so, how? If not, why not?  
Indications for, and 
optimal timing of, 
palliative care referral in 
heart failure 
In your opinion, what makes a heart failure patient eligible 
for palliative care? 
In your opinion what makes a heart failure patient 
appropriate for palliative care? 
Barriers to palliative care 
referral in heart failure  
What are some of the barriers that you believe might be 
impeding the uptake of palliative care in heart failure? 
If you suspect that a heart failure patient can benefit from 
palliative care, who do you believe is responsible for 
having this discussion [with the patient]? 
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Table 4.2. Hypothetical heart failure patient vignette used to frame interviews 
 
Characteristic   
Demographics 67-year-old, Caucasian male; married, 2 non-local children 
History • 3 hospitalizations within the past year for acute HF decompensation 
events 
• History of ST elevation myocardial infarct 5 years ago followed by 
coronary artery bypass grafting  
• On recent cardiac catheterization, has multi-vessel coronary artery 
disease with all grafts patent 
• No ischemia on stress testing and no angina symptoms 
BMI 34.5 kg/m2 
Ejection fraction 18% 
 
Transplantation Carefully reviewed by transplantation team and deemed ineligible for 
cardiac transplantation or other cardiac surgery due to age, kidney disease, 
and insulin-dependent diabetes 
Dyspnea 9/10 on exertion; 3/10 at rest 
Orthopnea 4-pillow orthopnea 
Edema Reports worsening bilateral lower extremity edema over the last 2 weeks 
Pain 5/10 over the past 2 weeks, in both legs and limiting walking 
Depression Moderate over the past 2 weeks 
Physical exam  Vitals: SBP 88, HR 80 
Neck: JVP elevated 10 cm 
Irregular rate, 3/6 systolic murmur consistent with mitral regurgitation 
Lungs with bilateral rales at both bases 
Abdomen normal 
Extremities: bilaterally edema, 2/4, pitting 
NT-ProBNP  2100 pg/mL 
Devices Implantable biventricular pacemaker - cardioverter-defibrillator; ventricular 
resynchronization x 3 years (not recent) 
Comorbidities • Atrial fibrillation  
• Major depression 
• Chronic kidney disease, stage 3, creatinine 2.5 mg/dl and has 
increased from 2.0 in the past 2 months 
• Hypertension; recently with hypotension due to heart failure and has 
not tolerated higher doses of antihypertensive medications 
• Type II diabetes mellitus 
Current 
medications 
• lisinopril 5 mg QD 
• furosemide 80 mg BID 
• carvedilol 3.125 mg BID 
• spironolactone 12.5 mg QD 
• insulin lispro  
• humulin n 
• bupropion xl 300 mg QD 
• warfarin  
Abbreviations: HF, heart failure; NT-ProBNP, N-terminal prohormone of brain natriuretic 
protein; BMI, body mass index; QD, daily; BID, twice daily; SBP, systolic blood pressure; 
HR, heart rate; JVP, jugular venous pressure.  
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Table 4.3. Techniques used to ensure qualitative rigor and trustworthiness of 
findings  
 
Aspect Technique Description 
Credibility 
How reflective are the 
research findings of 
reality?  
Field 
observation 
DK observed patient encounters in heart 
failure clinics and palliative care home 
visits during study design.  
Iterative 
questioning32 
We employed deliberate, explicit probes 
in order to understand participants’ 
responses with greater precision.  
Expert review 
of protocol 
Disciplinary experts assisted in the 
development of the interview guide and 
patient vignette.  
Frequent 
debriefing 
Weekly meetings were held between the 
lead and senior authors to discuss 
findings and concerns.  
Transferability 
How applicable are the 
research findings to other 
contexts or situations? 
Contextual 
review 
We performed a detailed literature review 
to understand the context within which our 
work falls.  
Dependability 
How reproducible are the 
research findings? 
Audit trail We maintained an extensive audit trail 
throughout the analytic process, detailing 
decision rules and justifications.    
Confirmability 
How objective was the 
analysis?  
Bracketing51  Recognition of investigators’ 
preconceptions and assumptions 
regarding the phenomena of interest.   
Triangulation Investigator triangulation (i.e., multiple 
researchers analyzed data) and 
disciplinary triangulation (i.e., researchers 
represented a variety of related expertise) 
  
 64 
Table 4.4. Characteristics of study participants 
 
 
Characteristic 
Full 
Sample 
n (%) 
Cardiology 
n (%) 
Primary 
Care 
n (%)  
Palliative 
Care 
n (%) 
N 18 6 6  6 
Age, median [range], years 42.5 [27-
57] 
39.5 [33-
56] 
46 [35-55]  52.5 [27-57] 
Female 11 (61) 3 (50) 3 (50)  5 (83) 
Race      
     White  16 (89) 4 (67) 6 (100)  6 (100) 
     African-American 1 (5) 1 (17) --  -- 
     Asian 1 (5) 1 (17) --  -- 
Years in practice, median      
[range] 
12 [2-38] 9.5 [2-23] 16.5 [7-32]  23 [3-38] 
Practice setting      
     Academic 12 (67) 4 (67) 6 (100)  2 (33) 
     Non-academic 5 (28) 1 (17) --  4 (67) 
     Both  1 (6) 1 (17) --  -- 
Current HF caseload, patients      
     0 1 (6) -- --  1 (20) 
     1-10 5 (28) -- 2 (33)  3 (50) 
     11-25 3 (18) -- 2 (33)  2 (40) 
     26-50 3 (18) 2 (33) 1 (17)  -- 
     51-100 2 (12) 1 (17) 1 (17)  -- 
     >100 3 (18) 3 (50) --  -- 
HF caseload in past year, 
patients 
     
     1-10 3 (18) -- 3 (50)  -- 
      11-25 2 (12) -- 1 (17)  1 (20) 
     26-50 5 (29) 1 (17) 2 (33)  2 (40) 
     51-100 2 (12) -- --  2 (40) 
     >100 5 (29) 5 (83) --  -- 
Legend: HF, heart failure. Columns may not total 100% due to rounding and missing 
data.  
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Figure 4.2. Qualitative themes identified in Aim 1 interviews 
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CHAPTER 5: COMPARING THE UNMET NEEDS OF COMMUNITY-BASED 
PALLIATIVE CARE PATIENTS WITH HEART FAILURE AND CANCER 
 
INTRODUCTION 
Palliative care seeks to optimize quality of life for patients and their families 
affected by serious illness, regardless of prognosis.1 One form of palliative care, hospice, 
is restricted to patients with an expected prognosis of six months or less. However, non-
hospice palliative care may be initiated at any point in the disease trajectory and may be 
administered in conjunction with curative or life-prolonging treatments. Palliative care 
includes: expert identification and management of pain and other symptoms; 
psychological, spiritual, and logistical support; assistance with treatment decision-
making and setting of care goals; and, complex care coordination.2 Palliative care has 
been shown to improve survival,3 quality of life,3,4 symptom burden,5 healthcare 
expenditures,2 and caregiver outcomes.6 Although palliative care may be thought of as a 
guiding approach to care,7 here the term indicates provision of care by a specialist 
palliative care provider or service.  
By its very nature, the predominant model of palliative care in the U.S., inpatient 
palliative care, is reactionary. Such consultations may focus more on symptom 
management related to the event precipitating the hospitalization, while paying less 
attention to proactive or holistic care, such as medication management, care goals 
discussion, complex care alignment across multiple providers, and transition 
coordination (e.g., hospital to skilled nursing or home).8 Accordingly, recent years have 
 72 
seen the emergence of community-based palliative care services, also known as 
“bridging programs.”9 Such services allow for longitudinal and prospective patient 
interaction, and are flexible enough to address patient needs across a variety of care 
settings, meeting patients and caregivers wherever they may find themselves (i.e., 
inpatient, outpatient, at patients’ place of residence), at any point in the illness trajectory.  
Indeed, outpatient palliative care programs have been labeled the “next frontier” in 
palliative care service delivery.10  
Historically, palliative care in the U.S. has largely served patients with cancer; 
however, this phenomenon seems to be changing.11  Nevertheless, patients with other 
serious illnesses may similarly benefit from palliative care.  One such condition is heart 
failure (HF), a progressive and incurable condition that is associated with extensive 
health services utilization, particularly at the end of life (Figure 5.1).12-16 More than 5 
million American adults currently suffer from HF, and it is estimated that 550,000 incident 
cases are diagnosed yearly.17 Given the high prevalence of HF and improved survival 
owing to life-prolonging therapies, the burden of chronic HF is greater than ever before, 
and is expected to grow.18 Patients with advanced HF suffer from physical 
symptoms,13,14,19 as well as psychosocial and emotional distress; 14,15 unresolved 
symptoms have a profound effect on patients with HF and their caregivers.20 The 
burdens typically experienced by patients with HF may not be markedly divergent from 
those of patients with cancer or chronic obstructive pulmonary disease (COPD); 
differences in symptom experience and distress may be a function of disease stage, as 
opposed to the diagnosis itself.21  
Despite the American College of Cardiology and the American Heart Association 
(ACC/AHA) recommending palliative and/or hospice care for patients with end-stage 
HF,22 HF patients tend to access such services far less often than cancer patients, 23 
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despite a similar illness experience and prognosis. Because lack of provider knowledge 
regarding palliative care may be a barrier to referring HF patients,7 HF patients who 
receive palliative care may ultimately present with more advanced symptoms than do 
patients with cancer. Moreover, little research has been conducted among patients with 
HF receiving palliative care, and most of this work has focused on inpatient or academic 
medical settings. Although community-based palliative care is a growing option in the 
U.S.,9,10 patients with HF are poorly represented, overall, in palliative care-related 
research.   
This study has three goals: (1) to describe a sample of HF and cancer patients 
referred for community-based palliative care services; (2) to determine the differential 
impact of having HF vs. cancer on unresolved symptoms and treatment gaps; and (3) to 
assess associations between primary diagnosis (i.e., HF vs. cancer) and outcomes such 
as performance status, adequate symptom control, and quality of life. All analyses were 
cross-sectional, at the patient level, and assessed at the time of first palliative care visit.   
 
METHODS 
Data Source 
The Carolinas Palliative Care Consortium is a quality improvement partnership 
between Duke University and three North Carolina community-based palliative care 
organizations.24 In June 2008, the Consortium established the Palliative Care Database, 
the first American initiative to systematically collect patient-, caregiver-, and provider-
reported data for quality monitoring purposes.24,25 At every visit, trained palliative care 
providers collected data using the Quality Data Collection Tool (QDACT).25,26 The 
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QDACT is a palliative care-specific assessment tool that can be completed on paper or 
by direct computerized entry, depending on user needs and preferences. Data are both 
stored locally at each site, and securely transferred to Duke University at regular 
intervals for analysis. In 2012, these retrospective quality improvement data were 
transitioned into what is known as the Palliative Care Research Registry (PCRR). The 
Duke University Institutional Review Board approved this study and the creation of the 
PCRR. The Institutional Review Board at the University of North Carolina at Chapel Hill 
additionally approved the study protocol.  
 
Procedures 
We extracted data from patients’ initial palliative care visits between June 1, 2008 
and January 1, 2012. We excluded data from one of the three palliative care institutions 
due to low patient counts. At each palliative care visit, Consortium providers used the 
QDACT to collect patient- or proxy-reported data.  Patients were asked to rate the 
severity, duration, and tolerability of 11 symptoms: agitation, anorexia, anxiety, 
constipation, depression, diarrhea, dyspnea, fatigue, insomnia, nausea, and pain using 
the McCorkle Symptom Distress Scale,27 a commonly used instrument in palliative 
populations. Proxy (i.e., provider or caregiver) ratings were substituted for patients when 
patients were unable to communicate independently (e.g., dementia, delirium, extreme 
frailty).   Providers documented whether the patient was receiving interventions 
(pharmacologic or non-pharmacologic) for pain, dyspnea, depression, and constipation. 
In addition, providers assessed patients’ quality of life (QOL), which is described in 
Measures.  
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Measures 
Dependent Variables: Our four dependent variables were: (1) number of 
unresolved symptoms; (2) number of treatment care gaps; (3) performance status; and, 
(4) palliative care patient health status (PC-PHS), a composite indicator of adequate 
symptom control and QOL.  We defined an “unresolved symptom” as a patient (or proxy) 
reported severity rating of “moderate” or “severe” for each of the 11 symptoms captured 
in the QDACT; counts could range from 0-11. Our use of the term “unresolved” signifies 
that symptoms persist at the time of first palliative care consultation – likely a reflection 
of the care received prior to palliative care referral. A “treatment gap” was defined as the 
lack of a documented intervention for a symptom rated as  “moderate” or “severe.” As 
interventions were documented for only four symptoms (listed previously), treatment gap 
counts could range from 0-4. All dependent variables were measured at the patient level.  
Performance status was assessed using the Palliative Performance Scale (PPS), 
version 2.028,  a modification of the Karnofsky Performance Scale that has been well-
validated in palliative care patients.29  The PPS uses an 11-category ordinal scale from 
0%-100% in ten-percentage point increments, with higher scores indicating better 
functioning.  As others have previously done, 8,30 we transformed PPS into a three-
category ordinal variable (low performance status: 0%-30%; medium performance 
status: 40%-60%; high performance status: 70%-100%) for clinical relevance and 
interpretability. 
Finally, we created PC-PHS, a composite indicator of symptom control and 
quality of life that summarized symptom management and quality of life outcomes. For 
symptom management, we focused on pain control and dyspnea, which are relevant to 
patients with advanced HF and cancer19,31 and are often targets of palliative care 
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interventions.  Providers asked patients about both their current and maximal tolerable 
level of each symptom.  If current symptoms were less than the maximum tolerable 
level, or if the patient reported no current symptom, we considered that patient to have 
adequate control.  QOL was assessed by providers using a single item measured on a 
3-category ordinal scale (i.e., “poor,” “fair,” “good”); this scale was derived from the 
McGill QOL Questionnaire Single Item Scale.32 Given the small proportion of patients 
who reported “good” QOL (5%), we created a binary measure (i.e., “poor” vs. “fair/good” 
QOL). The resulting PC-PHS variable is a binary indicator which takes the value of 1 if 
all 3 conditions were met (i.e., controlled pain, controlled dyspnea, and fair/good QOL), 
and 0 if otherwise. Presence of the PC-PHS outcome suggests better overall health, as 
it indicates adequate pain and dyspnea control, and fair/good QOL. We performed 
sensitivity analyses using various permutations of the composite PC-PHS variable (i.e., 
1-2 vs. 3 outcomes).  
Independent Variable:  Our independent variable was primary diagnosis, that is, 
HF or cancer.  Heart failure patients were identified by the following International 
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic 
codes: 428.xx (HF); 429.3 (cardiomegaly); 402.01 (malignant hypertensive heart disease 
with HF); 402.11 (benign hypertensive heart disease with HF); 402.91 (unspecified 
hypertensive heart disease with HF); and, 425.xx (cardiomyopathy).33 Cancer patients 
were defined by ICD-9-CM diagnostic codes in the range of 140-239.9. Four patients’ 
records listed both HF and cancer diagnoses; these patients were excluded from 
analysis.  
Control Variables:  Recognizing that patients who receive palliative care 
consultations while hospitalized likely differ regarding acuity, we included a binary 
indicator to control for location of consultation. Additional control variables included: 
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patient age, gender, race, and a binary indicator reflecting whether symptom 
assessment data were patient- vs. proxy-reported.    
 
Statistical analysis 
After describing the sample, we used Pearson’s chi-square tests, unpaired 
Student’s t-tests and Wilcoxon-Mann-Whitney tests to examine bivariate differences 
between disease cohorts. Next, we conducted several multivariate analyses to estimate 
the impact of primary diagnosis on unresolved symptom, treatment gap, and PC-PHS 
outcomes between HF and cancer patients at the time of first palliative care consultation. 
First, we used Poisson regression to estimate models of predicted counts of unresolved 
symptoms and treatment gaps.34 We chose the Poisson estimator due to absence of 
overdispersion and superior model performance, as compared to negative binomial 
regression.34 Second, we estimated risk ratios (RRs) to assess the effect of primary 
diagnosis on the probability of the PC-PHS outcome. We chose RRs given the 
frequency of our study outcome, as odds ratios may overstate relative risk in situations 
of non-rare outcomes.35 We calculated RRs using modified Poisson regression with 
robust/sandwich standard errors.36 This method has been shown to estimate RRs 
consistently and efficiently in samples as small as 100.35 We compared RR point 
estimates calculated from this Poisson method and manually from 2x2 contingency 
tables and found them to be exact within two decimal places. Third, we employed 
generalized ordered logistic regression to model the effects of primary disease on 
performance status (i.e., PPS).37,38 We chose a partial proportional odds model, as a 
Brant test revealed that our data violated the proportional odds assumption necessary 
for unbiased estimation of a standard ordered logistic model. We used Stata “gologit2” 
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with the “autofit” option to estimate this model.38 Average marginal effects are provided 
for the generalized ordered logistic regression for ease of interpretability. Average 
marginal effects express the average change in the probability of an outcome occurring 
attributable to a specific variable, keeping all else in the model constant.  
The sample size had a sufficient number of cases to conduct all multivariable 
analyses using the 10:1 event-to-variable ratio.39,40 We assessed model fit by plotting 
fitted data vs. both actual data points and deviance residuals. Various sensitivity 
analyses were conducted to assist in model specification decisions and diagnostics 
(e.g., variable recoding, additional control variables). We also conducted formal tests of 
normality, heteroscedasticity, and multicollinearity to ensure proper modeling. Statistical 
tests were two-tailed with a critical α-level of 0.05. Analyses were conducted using 
Stata/IC, version 12.41  
 
RESULTS 
Cohort characteristics 
Of 1,031 patients meeting study criteria, 334 (32%) had a primary diagnosis of 
HF and 697 (68%) had cancer (Table 5.1). Overall, our patients were predominantly 
White, and 45% were male. Nearly 70% of encounters were in an inpatient hospital 
setting. The majority of patients from both disease groups had initiated advance care 
planning, most often a “do not resuscitate” order. At baseline, the median PPS score for 
all patients was 40%, indicating a predominantly bedfast patient with extensive evidence 
of disease, requiring assistance for self-care tasks. Approximately half of each disease 
group reported fair/good QOL. Compared to cancer patients, those patients with HF 
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were significantly older, (84 years vs. 71 years, P<0.001), had at least one prior 
hospitalization in the preceding six months (81% vs. 63%, P<0.001), and more likely to 
reside in a nursing home (18% vs. 4%, P<0.001).    
 
Effect of primary diagnosis on symptom and treatment gap prevalence 
HF patients presented with fewer unresolved symptoms than did cancer patients, 
both at moderate/severe levels (1.77 vs. 2.24, P=0.0001, Table 5.2), and overall (3.36 
vs. 3.87, P=0.0002, data not shown). HF patients, relative to cancer patients, less 
frequently rated the following symptoms as moderate/severe: anorexia (29% vs. 46%, 
respectively, P<0.001), pain (19% vs. 32%, P<0.001), insomnia (14% vs. 20%, P=0.02), 
anxiety (12% vs. 20%, P=0.002), constipation (8% vs. 15%, P=0.004), and nausea (4% 
vs. 13%, P<0.001). Only dyspnea was more commonly reported by HF than cancer 
patients as moderate/severe (25% vs. 18%, respectively, P=0.02) (Figure 5.2). HF 
patients more commonly experienced dyspnea treatment gaps (17% vs. 8%, P<0.001, 
Figure 5.3), whereas cancer patients more frequently had constipation-related treatment 
gaps (11% vs. 6%, P=0.008).  
Compared to cancer patients, an HF diagnosis was significantly associated with 
a 13.8%-reduction in the predicted number of unresolved symptoms per patient, after 
accounting for the control variables (Table 5.3). However, we did not detect a statistically 
significant association between primary diagnosis and predicted number of treatment 
gaps (Table 5.3).  
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Effect of primary diagnosis on palliative care patient health status at first consultation 
In bivariate analysis, having HF as a primary diagnosis was not significantly 
associated with the probability of experiencing differential overall patient health status as 
defined by the PC-PHS composite outcome (unadjusted RR: 1.20, 95% confidence 
interval [CI]: 0.96, 1.50, Table 5.4). However, after adjusting for clinical and demographic 
factors, HF was associated with a decreased probability of positive health status (as 
captured by PC-PHS), compared to cancer patients (adjusted RR: 0.70, 95% CI: 0.55, 
0.90).   
 
Effect of primary diagnosis on performance status at first consultation  
A primary diagnosis of HF was significantly associated with a greater probability 
of medium performance status (i.e., PPS = 40%-60%) at first visit (average marginal 
effect: 0.11, 95% CI: 0.033, 0.187), but a lower probability of high performance status 
(i.e., PPS = 70%-100%) (average marginal effect: -0.065, 95% CI: -0.118, -0.011), 
compared to cancer patients. To assess model performance, we compared predicted 
probabilities of each PPS outcome category to observed sample frequencies, and found 
them to be similar within two decimal points. 
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DISCUSSION 
We investigated differences regarding unresolved symptom burden, treatment 
gaps, and outcomes between HF and cancer patients referred for community-based 
palliative care.  This work extends the literature beyond previous efforts in two important 
ways. First, our sample is larger, allowing us to conduct more sophisticated analyses 
while controlling for important covariates.  Second, our study is the first to examine these 
questions among community-based palliative care, a growing venue for palliative care in 
the U.S.9 
Findings support the notion that HF patients possess care needs that are clearly 
within the purview of palliative care, even if not at the same level of severity or frequency 
experienced by the classic palliative care population – patients with advanced cancer. 
Two studies explicitly comparing HF and cancer patients’ physical and psychosocial 
needs found the groups to be indistinguishable vis-à-vis symptom burden, but that 
differences existed regarding specific symptom prevalence.15,21,42 Our findings are 
generally concordant with their results. Cancer patients in our study reported greater 
symptom burden, as reflected by the number of unresolved symptoms at moderate or 
severe levels; whether the observed difference in the number of unresolved symptoms 
between cancer and HF patients (i.e., 2.24 vs. 1.77 moderate/severe symptoms) is 
sufficient to affect clinical decision-making is unknown, but our general clinical 
experience suggests that symptom prioritization becomes paramount when people are 
suffering from multiple problems simultaneously. Nevertheless, the question remains 
whether it is overall cumulative symptom burden or the severity of a specific symptom 
that prompts provider intervention.  Echoing previous work,42,43 we found dyspnea to be 
more prevalent in HF patients than in cancer patients; shortness of breath, like pain, is a 
high priority symptom that must be addressed or quality of life degrades and caregiver 
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burden escalates.43-47 Lastly, a diagnosis of HF was associated with poorer health status 
(as measured by our composite PC-PHS outcome); this finding persisted even after we 
controlled for the advanced age of our HF patients. As with most advanced illnesses, 
particularly those illnesses involving the elderly, our findings suggest that patients with 
advanced HF and cancer are appropriate for palliative care; however, the pattern of 
disease burden appears to differ between the two illnesses and therefore the portfolio of 
palliative interventions must be appropriately tailored.   
Our findings are not intended to obviate disease-specific policies and palliative 
care referral for HF and cancer patients. Indeed, we strongly caution against such 
conclusions. Despite overarching similarities regarding disease-related burden, we 
contend that the natural histories of HF and cancer patients require different approaches 
to optimize palliative care. Particularly for diseases with notoriously unpredictable 
trajectories, such as HF,48 the timing of palliative care referral must be customized to 
patients’ needs and preferences if the goal is a more patient-centric experience. 
Because palliative care can be administered at different points in the illness trajectory, its 
introduction and intensity might best be tailored to patients’ specific incident and 
fluctuating needs (e.g., HF-related comorbidities, use of morphine for dyspnea, advance 
care planning). By introducing palliative care before symptoms become intractable or 
hospice enrollment is the only option, one can offer patients and caregivers an array of 
supportive services that are consistent with their needs and goals for care.49,50 Another 
noteworthy finding in our study is the advanced age of our patients (median: 85 years), 
which combined with a HF diagnosis, may point to a short life expectancy. This may 
perhaps point to a possible selection issue in that HF patients are being referred for 
palliative care at a point in their illness experience when hospice care may be more 
appropriate. Previous work has documented confusion amongst medical providers 
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regarding non-hospice palliative care and hospice care,7 which also may suggest that 
HF patients are currently being referred for palliative care later in their illness than is 
ideal for optimal integration of palliative and standard cardiac treatments.  
Whereas numerous studies have demonstrated the benefits of palliative care to 
patients with cancer,3,4,51 the role of palliative care for cardiac conditions, including HF, 
has yet to be clearly defined.7,52,53 As such, ACC/AHA recommendation of palliative care 
for patients with advanced HF is largely based upon consensus, rather than empirical 
evidence. Although it is encouraging that palliative care is included in treatment 
guidelines put forth by the ACC/AHA,22 it is important to note that these 
recommendations are discussed in the context of end-of-life care. Such guidelines are 
likely to further exacerbate the misconception that non-hospice palliative care and 
hospice care are synonymous amongst healthcare providers. Educational efforts to 
correct such misconceptions and to clearly emphasize what palliative care can offer 
patients and referring providers, as well as how it can be accessed locally may be 
worthwhile; preliminary research suggests that cardiology and primary care providers 
may be receptive to such interventions.7  
Regrettably, symptoms experienced by HF patients may go unrecognized and 
unaddressed.54 Dyspnea and fatigue are characteristic of HF,55 yet the literature and our 
data support that HF patients may suffer from various other symptoms including pain, 
depression, insomnia, anorexia, anxiety, edema, and constipation.14,55-57 Thus, although 
most unaddressed symptoms were more common in our cancer cohort, we must not 
diminish the need for thorough clinical assessment and management among HF 
patients.  
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This study has several limitations. First, we combined all cancer patients, which 
precludes our ability to identify differences related to tumor type. Second, PC-PHS is a 
composite measure. Although it has face validity and was based on clinical and intuitive 
logic, the PC-PHS has not been validated and may represent another source of 
measurement bias. Perhaps future multi-site studies with larger sample sizes should 
employ disease-specific measures to complement generic measures of QOL and 
functioning. Third, we were limited in our ability to control for potential confounders by 
the data available in PCRR. Notably, patients with HF were substantially older than were 
those patients with cancer. Thus, we cannot separate the effect of age from disease. 
Moreover, data from a quality-monitoring database may be less accurate and consistent 
than research databases, although more reflective of care as actually delivered in usual 
practice. Fourth, given the cross-sectional nature of this study, the types of conclusions 
that can be drawn are limited. Finally, our data come from two community-based 
palliative care organizations in North Carolina, which may limit generalizability to other 
care settings and regions. The patients in this study all had been referred for palliative 
care consultation, and may therefore differ from HF and cancer patients who were not 
referred to palliative care. 
Our study is the first HF-focused analysis of a database profiling community-
based palliative care practice in the U.S. As such, we hope that it will serve as a first 
step to describe a model of care through which we may expect a growing number of HF 
patients to receive supportive services.10,16 Additionally, given the increasing prevalence 
of HF, we hope that this work will spark discussion regarding palliative care workforce 
planning especially as it relates to ensuring that palliative care teams have the skills and 
resources necessary to take care of people with HF. Lastly, we hope that this work will 
draw providers’ attention to sources of distress in HF patients that may currently be 
 85 
going unnoticed and undertreated. Providers may lack clarity regarding how to best 
leverage specialist palliative care services to support their efforts to optimize HF patient 
experiences.7,52,58,59 Methodologically rigorous, clinically relevant, and patient-centered 
clinical and health services research is needed to elucidate the potential role of palliative 
care in HF, given the anticipated growth of this population over the coming decades.   
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FIGURES AND TABLES 
Figure 5.1. Illustration of a proposed model of palliative care and hospice 
integration across the heart failure trajectory 
 
 
Abbreviations: HF, heart failure; ACC/AHA: American College of Cardiology/American 
Heart Association; NYHA: New York Heart Association 
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Table 5.1. Demographic and disease characteristics of study cohort 
 
Characteristic Heart Failure 
Patients 
N (%) 
Cancer 
Patients 
N (%) 
P-
value 
N 334 697  
Age in years, median [range] 84 [33-102] 71 [12-101] <0.001 
Male gender 138 (41) 327 (47) 0.09 
Race 0.001 
   White 302 (90) 602 (86)  
   Black 16 (5) 78 (11)  
   Other or unknown 16 (5) 17 (2)  
Advance care planning activities completed prior to or during initial palliative care visit 
   “Do not resuscitate” status declaration  217 (65) 472 (68) 0.64 
   Living will completed 136 (41) 249 (36) 0.003 
   MOST form completed 16 (5) 24 (3) 0.30 
   Designation of healthcare surrogate 191 (57) 472 (68) <0.001 
Number of hospitalizations within 6 months before first palliative care visit <0.001 
   0 64 (19) 256 (37)  
   1 90 (27) 183 (26)  
   2 53 (16) 97 (14)  
   3 28 (8) 38 (5)  
   >3 17 (5) 15 (2)  
   Unknown  82 (25) 108 (15)  
Care setting at time of first palliative care visit <0.001 
   Hospital inpatient 230 (69) 544 (78)  
   Nursing home or assisted living facility 61 (18) 30 (4)  
   Patient home 25 (8) 83 (12)  
   Outpatient clinic 1 (0.3) 6 (0.7)  
Respondent 0.03 
   Patient 222 (66) 507 (73)  
   Caregiver or provider 110 (33) 183 (26)  
Palliative Performance Scale, median 
[range] 
40 [10-80] 40 [10-90] 0.27 
   Low (10%-30%) 92 (28) 236 (34)  
   Medium (40%-60%) 154 (46) 296 (42)  
   High (70%-100%) 13 (4) 74 (11)  
General quality of life rating    0.99 
   Poor 134 (40) 301 (43)  
   Fair/Good 153 (46) 344 (49)  
Note: Values may not sum to 100 due to rounding and/or missing data. MOST = Medical 
Orders for Scope of Treatment. The Palliative Performance Scale rates functional status 
across five domains from 0%-100% in 10-percentage point increments, with greater 
scores indicating higher performance. Chi-square tests of independence were calculated 
for categorical variables, Student’s t-tests were used for normally distributed continuous 
variables, and Wilcoxon-Mann-Whitney tests calculated for interval or non-normally 
distributed continuous outcomes.  
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Table 5.2. Comparison of unresolved symptoms and treatment gaps between 
heart failure and cancer patients referred for palliative care 
 
Variable HF patients 
(N=334) 
Cancer patients 
(N=697) 
P-
value 
Symptoms reported at any moderate or 
severe levels, mean ± SD [range] 
1.77 ± 1.60 [0-
9] 
2.24 ± 1.82 [0-
10] 
0.0001 
Treatment gaps per patient, mean ± SD 
[range]   
0.40 ± 0.037 
[0-4] 
0.40 ± 0.025 [0-
4] 
0.98 
Note: Abbreviations: HF, heart failure; SD, standard deviation.  
The number of symptoms reported at any level is provided only for contextual purposes, 
but was not used as an outcome in our analyses.   
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Figure 5.2. Prevalence of unresolved symptoms at first palliative care consultation 
 
 
Note: A symptom was defined as “unresolved” when its current severity was rated as 
either “moderate” or “severe.”  
* Pearson’s chi-square test indicates significant difference in unresolved symptom 
prevalence between heart failure and cancer patients at the α=0.05 level.  
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Figure 5.3. Prevalence of treatment gaps at first palliative care consultation 
 
 
Note: We defined a “treatment gap” as the lack of a documented intervention for a 
symptom rated as  “moderate” or “severe.”  
*: Pearson’s chi-square test indicates significant difference in treatment gap prevalence 
between heart failure and cancer patients at the α=0.05 level.  
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Table 5.3. Results of Poisson models estimating the effect of primary diagnosis on 
unresolved symptom and treatment gap prevalence at the time of first palliative 
care consultation 
 
Variable β (SE) 95% CI Percent 
change 
Outcome: Expected number of unresolved symptoms  
Heart failure (vs. cancer) -0.148 (0.069)* -0.285, -0.012 -13.8 
Age, years -0.0055 
(0.0021)** 
-0.0096, -
0.0014 
-0.5 
Male gender -0.099 (0.057) -0.212, 0.012 -9.5 
Non-White race -0.008 (0.087) -0.178, 0.161 -0.8 
Palliative Performance Scale -0.0020 (0.0017) -0.0054, 
0.0014 
-0.2 
Proxy-reported symptom 
assessment 
-0.046 (0.073) -0.189, 0.096 -4.5 
Outpatient -0.063 (0.080) -0.220, 0.094 -6.2 
Outcome: Expected number of treatment gaps 
Heart failure (vs. cancer) 0.23 (0.13) -0.03, 0.48 25.3 
Age, years -0.0076 
(0.0037)* 
-0.0149, -
0.0002 
-0.8 
Male gender 0.12 (0.11) -0.11, 0.34 12.6 
Non-White race -0.10 (0.20) -0.49, 0.28 -9.7 
Palliative Performance Scale 0.0016 (0.0036) -0.0054, 
0.0086 
0.2 
Proxy-reported symptom 
assessment 
-0.03 (0.14) -0.31, 0.25 -3.1 
Outpatient -0.46 (0.17)** -0.79, -0.13 -36.8 
Note: β, Regression coefficient; SE, Standard error; CI, confidence interval. 
Sandwich-robust standard errors provided.  
The percent change in the expected count of an outcome for a δ-unit change in variable 
k, holding all else constant, is calculated as: 100 ∗ exp 𝜷𝜿 ∗ 𝜹 − 𝟏 .34  
 *: Significant at the 5% level. **: Significant at the 1% level.   
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Table 5.4. Associations between various demographic and clinical variables and 
palliative care patient health status at first palliative care consultation 
 
Variable 
 RR (95% CI)  
Unadjusted P-value Adjusted P-value 
Heart failure (vs. cancer) 1.20  
(0.96-1.50) 
0.11 0.70  
(0.55-0.90)** 
0.01 
Age, in years 1.01  
(1.00-1.02)** 
0.01 1.02  
(1.01-1.03)** 
<0.001 
Male gender 0.75  
(0.62-0.92)** 
0.01 1.34  
(1.10-1.62)** 
0.003 
Non-White race 1.24  
(0.88-1.73) 
0.22 0.86 (0.62-
1.20) 
0.37 
Proxy-reported symptom assessment (vs. 
patient-reported) 
1.69  
(1.30-2.20)** 
<0.001 0.58  
(0.45-0.76)** 
<0.001 
Outpatient (i.e., not hospitalized) at time of 
visit 
0.75  
(0.61-0.93)** 
0.01 1.27  
(1.04-1.57)* 
0.02 
Note: Abbreviations: RR, risk ratio; CI, confidence interval. 
*: Significant at the 5% level. **: Significant at the 1% level. 
The outcome variable (PC-PHS, palliative care patient health status) was a binary 
indicator defined as positive if a patient reported all three of the following criteria: 
fair/good quality of life; adequately controlled pain; and, adequately controlled dyspnea.   
Akaike’s Information Criterion (AIC) of adjusted model: 1.24  
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Table 5.5. Average marginal effects after generalized ordered logistic regression 
of Palliative Performance Scale score at first visit 
 
Variable 
Average marginal effect 
(SE) 
P-
value 95% CI 
Probability of low PPS (0%-30%) at first visit 
Heart failure -0.045 (0.032) 0.16 -0.11, 0.018 
Age, years -0.00045 (0.00099) 0.65 -0.0023, 
0.0015 
Male gender -0.015 (0.024) 0.53 -0.062, 0.032 
Non-White race -0.016 (0.036) 0.66 -0.087, 0.055 
Proxy-reported symptom 
assessment 
0.406 (0.018)** <0.001 0.370, 0.440 
Outpatient -0.354 (0.049)** <0.001 -0.451, -0.257 
Probability of medium PPS (40%-60%) at first visit  
Heart failure 0.110 (0.039)* 0.01 0.033, 0.187 
Age, years 0.0019 (0.0010) 0.06 -0.00009, 
0.0039 
Male gender 0.007 (0.12) 0.53 -0.016, 0.031 
Non-White race 0.008 (0.018) 0.66 -0.027, 0.043 
Proxy-reported symptom 
assessment 
-0.199 (0.020)** <0.001 -0.24, -0.16 
Outpatient 0.265 (0.051)** <0.001 0.016, 0.366 
Probability of high PPS (70%-100%) at first visit 
Heart failure -0.065 (0.027)* 0.02 -0.118, -0.011 
Age, years -0.0015 (0.00063)* 0.02 -0.003, -0.0002 
Male gender 0.008 (0.012) 0.53 -0.016, 0.032 
Non-White race 0.008 (0.019) 0.66 -0.028, 0.044 
Proxy-reported symptom 
assessment 
-0.207 (0.024)** <0.001 -0.253, -0.160 
Outpatient 0.089 (0.020)** <0.001 0.049, 0.130 
Note:  
Abbreviations: SE, Standard error; CI, confidence interval; PPS, Palliative Performance 
Scale. The PPS rates functional status across five domains from 0%-100% in 10-
percentage point increments, with greater scores indicating higher performance. 
*: Significant at the 5% level. **: Significant at the 1% level.  
Average marginal effects indicate the average difference in the probability of a patient 
experiencing one of the three PPS outcome categories, controlling for all other factors in 
the model. Average marginal effects computed using “margins” command of Stata 
version 12. 
Pseudo-R2: 0.21.   
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CHAPTER 6: ASSESSING THE QUALITY OF PALLIATIVE CARE RECEIVED 
BY PATIENTS WITH HEART FAILURE LIVING IN THE COMMUNITY 
 
INTRODUCTION 
Heart failure (HF) is a prevalent, chronic, and ultimately incurable condition that 
is associated with extensive health services utilization, particularly at the end of life.1-5 
Given the increasing incidence of HF and improved survival owing to life-prolonging 
therapies, the burden of chronic HF both in terms of morbidity and mortality, as well as 
healthcare costs, is greater than ever before, and is expected to grow.6 Historically, our 
understanding regarding HF healthcare quality has centered on the relationship between 
provider/facility processes of care (e.g., appropriate use of cardiac drugs, devices, and 
procedures) and outcomes such as post-hospitalization readmission and mortality.7-11 
Recently, a growing effort has begun to examine end-of-life experiences of HF patients 
to reflect the quality of care that such individuals receive. To date, such research has 
predominantly assessed hospice utilization trends in Medicare claims12 or large clinical 
registries.13  
Traditionally, palliative care services in the U.S. have been administered in the 
inpatient setting; however, emerging models of care, such as community-based and 
outpatient palliative care hold promise for creatively addressing the increasing demand 
of patients needing support living with chronic diseases, such as HF.14,15 Community-
based palliative care is an attractive approach for people with advanced HF given its 
flexibility to provide care for patients despite volatile disease trajectories with multiple 
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transitions across care settings (e.g., home, hospital, skilled nursing) and treatment 
modalities. The ability for palliative care to extend beyond acute care hospitalizations is 
especially critical for frail patients, who, for example, may experience added burdens or 
barriers as a result of traveling to accessible palliative care services.  
The role of palliative care has yet to be clearly defined in cardiology.16-18 To 
deliver high quality palliative care to patients with HF, it is imperative to prospectively 
study processes of care and outcomes, as people with HF transition between care 
settings in a natural, “real world” context. The goal of this study was to examine the 
relationship between quality metrics for palliative processes and patient outcomes in 
community-based palliative care in a cohort of HF patients.  
 
METHODS 
Data Source 
The Carolinas Palliative Care Consortium is a quality improvement partnership 
between Duke University and three North Carolina community-based palliative care 
organizations.19 In June 2008, the Consortium established the Palliative Care Database, 
the first American initiative of its kind to systematically collect patient-, caregiver-, and 
provider-reported data for quality monitoring purposes.19,20 At every consultation, trained 
palliative care providers collected data using the Quality Data Collection Tool 
(QDACT).20,21 Data are both stored locally at each site, and securely transferred to Duke 
University at regular intervals for mining and analysis. In 2012, these retrospective 
quality improvement data were transitioned into what is known as the Palliative Care 
Research Registry (PCRR). The Duke University Institutional Review Board approved 
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this study and the creation of the PCRR. The Institutional Review Board at the University 
of North Carolina at Chapel Hill additionally approved the study protocol. 
 
Procedures 
We extracted consultation data entered from June 1, 2008 until January 1, 2012. 
HF patients were identified by the following International Classification of Diseases, 
Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic codes: 428.xx (HF); 429.3 
(cardiomegaly); 402.01 (malignant hypertensive heart disease with HF); 402.11 (benign 
hypertensive heart disease with HF); 402.91 (unspecified hypertensive heart disease 
with HF); and, 425.xx (cardiomyopathy).22 We included only patients with at least two 
consultations to allow for process performance and a subsequent effect on patient 
outcomes, if any. To assess the association between palliative care processes and end-
of-life outcomes, we restricted our cohort to patients for whom we could confirm death by 
January 2012 via the Social Security Administration Death Master File and obituary 
notices accessed using www.ancestry.com. Such sources have a high degree of 
sensitivity in identifying mortality.23  
 
Measures 
Quality of palliative care was assessed based upon the “Prepare, Embrace, 
Attend, Communicate, and Empower” (PEACE) indicator set developed for the Centers 
for Medicare and Medicaid Services (CMS).24 Quality measures identified from a 
literature review were pilot-tested, and subsequently evaluated by a 14-member expert 
panel. Of the 34 adopted indicators, 14 could be assessed within the PCRR. We chose 
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to focus our analysis on the subset of indicators believed by providers to be the most 
likely to positively influence patient outcomes. To reduce the number of quality indicators 
used in this study, we electronically surveyed a convenience sample of 14 North 
Carolina providers in cardiology, primary care, or palliative care.18 With a median of 12 
years (range: 2-38) in practice, the provider raters were clinically knowledgeable to 
comment on the quality indicators. Providers were asked to select the top three 
indicators which they believed were “likely to be valid indicators of overall high-quality 
HF care, so much so that it would be appropriate on which to base CMS reimbursement 
decisions (bonuses or penalties).” We chose the five indicators most frequently selected 
in the survey (Figure 6.1). The quality indicator for symptom assessment was met if all 
eleven symptoms assessable in the QDACT were evaluated at the first palliative care 
consultation. Similarly, the dyspnea indicator measured whether a clinical assessment of 
dyspnea was performed at the first consultation. If patients screened positive for 
dyspnea, a subsequent quality indicator reflected initiating pharmacologic or non-
pharmacologic treatment by the end of the following consultation.  The comprehensive 
assessment indicator was scaled as a binary variable (scored 0 and 1) with a score of 1 
requiring all of the following: (1) the clinical screening of at least one symptom, (2) a 
quality of life (QOL) assessment, and (3) the assessment of any advance care planning 
activities. Finally, the indicator for preferences for life-sustaining treatments required 
completion of a living will, a Medical Orders for Scope of Treatment (MOST) form, or 
having declared “full code” or “do not resuscitate” status prior to or during the first 
palliative care consultation. Each indicator was dichotomized (i.e., present = 1 or absent 
= 0).   
During palliative care consultations, Consortium providers assessed three 
patient-reported outcomes that are both meaningful to patients at the end of life25 and 
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key targets of palliative intervention: QOL, adequately controlled pain, and adequately 
controlled dyspnea. For QOL, we used a single item, scored on a three-category ordinal 
scale (i.e., “poor,” “fair,” “good”) derived from the McGill QOL Questionnaire Single Item 
Scale;26 given the small proportion of patients who reported “good” QOL at both initial 
and terminal consultations (5% and 7%, respectively), we created a binary measure (i.e., 
“poor” versus “fair/good” QOL). Pain and dyspnea assessments were made using the 
McCorkle Symptom Distress Scale,27 a commonly used instrument in palliative care 
populations. The PCRR includes information regarding the severity, duration, and 
tolerability of 11 symptoms: agitation, anorexia, anxiety, constipation, depression, 
diarrhea, dyspnea, fatigue, insomnia, nausea, and, pain.  For pain and dyspnea, 
providers asked patients about both their current and maximal tolerable levels of pain 
and dyspnea.  If current symptom severity was less than the maximum tolerable level, or 
if the patient reported no current symptom, we considered that patient to have adequate 
control. We initially modeled the three components separately (i.e., fair/good QOL, 
adequately controlled pain, and adequately controlled dyspnea); however, in the interest 
of parsimony, we chose to combine the outcomes into a single composite variable (2-3 
versus 0-1 outcomes). That is, we created a binary variable (scored 0 and 1), with 1 
requiring the presence of at least two of the three components: fair/good QOL, 
adequately controlled pain, and adequately controlled dyspnea. We performed sensitivity 
analyses using various permutations of the composite variable (i.e., >1 outcome, all 3 
outcomes). We will refer to this composite outcome as “palliative care patient health 
status” or PC-PHS.  
Performance status was assessed using the clinician-reported Palliative 
Performance Scale (PPS), version 2.028,  a modification of the Karnofsky Performance 
Scale that has been well-validated in palliative care patients.29  The PPS uses an 11-
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category ordinal scale from 0-100% in 10-percentage point increments, with higher 
scores indicating better functioning. Recognizing that patients who receive palliative care 
consults while hospitalized likely differ regarding acuity, we included a binary indicator to 
control for location of consult. Additional control variables included patient: age, gender, 
race (white or non-white), sum of palliative care consultations recorded in the PCRR, 
and a binary indicator reflecting whether symptom assessment data were patient- versus 
proxy-reported.    
 
Statistical analysis 
After describing the sample, we conducted a two-step process to assess the 
process-outcome link. First, we regressed the composite outcome on each quality 
indicator, to provide unadjusted risk ratios (RRs). Next, we simultaneously adjusted for 
all of the quality indicators, as well as a one-variable patient adjustment score. In the 
second step, we did not include the quality indicator regarding dyspnea treatment, as it 
by definition, applies only to a small subset of our overall cohort.  
We calculated RRs using modified Poisson regression with robust/sandwich 
standard errors.30 This method has been shown to estimate relative risk consistently and 
efficiently in samples as low as 100. We compared RR point estimates calculated from 
this Poisson method and manually from 2x2 contingency tables and found them to be 
exact within two decimal places. Risk ratios were chosen given the frequency of our 
study outcome, as odds ratios may overstate relative risk in such situations.31 
Given the limited and fixed sample size, we constructed a patient-level 
adjustment score to reduce the dimensionality of regression models; this technique has 
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been previously applied to similar studies of healthcare quality assessment.32,33 
Variables in the adjustment score were: (1) age at time of first palliative care 
consultation; (2) gender; (3) race; (4) patient versus proxy report; (5) care setting (i.e., 
hospital inpatient versus patient’s home); and, (6) total number of palliative care 
consultations recorded in the PCRR. We attempted to include performance status (as a 
proxy for disease status and prognosis) in the adjustment model; however, it was 
excluded due to multicollinearity with number of palliative care consultations.  
The sample size for this study theoretically provided sufficient cases to conduct 
the multivariable analysis, while maintaining an event per variable ratio higher than 10 to 
1 in all multivariable models.34,35 Specifically, given the four quality indicators that applied 
to all patients, in addition to the single patient adjustment variable, our sample size of 85 
(of which 60 experienced the composite outcome) was deemed to be sufficient. We 
assessed model fit by plotting fitted versus actual data points. Statistical tests were two-
tailed with a critical α-level of 0.05. Analyses were conducted using Stata/IC, version 
12.36  
RESULTS 
Cohort characteristics 
A total of 85 patients met all study criteria. Our predominately White cohort (93%) 
was almost equally split regarding gender (53% female) (Table 6.1).  The median age 
was 85 years (range: 35-101). Median duration of palliative care enrollment was 76 days 
(range: 1-1,075), and 75.3% of patients died within 60 days of their last palliative care 
consultation (data not shown). The median number of palliative care consultations per 
patients was 3 (range: 2-24).   
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Prevalence of quality indicator adherence 
Overall, we documented a 48% joint adherence rate to the four quality indicators 
that applied to all HF patients (Table 6.2). Taken individually, we noted highest 
adherence to the receipt of an initial dyspnea assessment (99%), and lowest for 
assessment of all eleven symptoms captured by our data collection instrument (59%). 
When this number was reduced to five symptoms, adherence rose to 94% (data not 
shown); however, for the remainder of this analysis, we refer to a “complete symptom 
assessment” as all eleven symptoms. Table 6.3 displays the prevalence of the PC-PHS 
variable, as well as its individual components.  
 
Patient clinical and demographic adjustment 
The unadjusted associations between the individual components in the one-
variable adjustment score and PC-PHS (composite outcome) are displayed in Table 6.4. 
Overall, the unadjusted RR for the adjustment score and PC-PHS was 3.87 (95% 
confidence interval [CI]: 1.15-13.02) per unit increase in adjustment score. That is, for 
each added item in the adjustment score, patient health status improved.  
 
Associations between quality indicator adherence and outcomes at last palliative care 
consultation 
Of the five unadjusted RRs (Table 6.5), only dyspnea assessment at initial 
consultation was associated with our composite outcome of PC-PHS (unadjusted RR: 
 108 
1.42, 95% CI: 1.24-1.64). In the multivariate model adjusting for palliative processes of 
care and patient characteristics (using the univariate adjustment score), the dyspnea 
assessment indicator was no longer significant (adjusted RR: 1.57, 95% CI: 0.93-2.64, 
p=0.09). However, we found a significant association between the presence of a 
comprehensive assessment and improved PC-PHS (adjusted RR: 1.40, 95% CI: 1.08-
1.80, p=0.01).  
 
DISCUSSION 
Within a cohort of community-dwelling patients with HF, we describe adherence 
to accepted palliative care quality indicators, and assess the link between these process 
metrics and patient health outcomes at the end of life. To our knowledge, this study is an 
initial step towards understanding the relationship between type of palliative care and 
outcomes among patients with HF living in the community. Our work presents novel 
contributions to the literature by: (1) focusing on community-based palliative care for HF 
patients; (2) leveraging the PCRR, which to date, is the largest US database capturing 
prospective palliative care quality performance data at the point of care; and (3) 
identifying associations between the PEACE quality indicators and meaningful patient 
outcomes. Notably, to make our results more relevant, we sought input from a 
multidisciplinary and experienced group of providers within North Carolina about the 
quality indicators they perceived to be most important. By aligning our data source with 
providers of the same region, we may have addressed some regional variations in 
provider-related treatment patterns;37,38 while this may have decreased generalizability 
outside of North Carolina, we believe that overall this process improves the applicability 
of our work.  
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Our work highlights an initial effort to align the resources (i.e., clinical, research, 
and information technology) to collect and assess quality performance data in 
community-based palliative care. This effort is critical to our understanding of the 
disease experiences of patients with advanced illness living in the community, as such 
benchmarking affords the opportunity to set the priorities of palliative medicine. The 
assessment of the process-outcome link will allow future prioritization of the processes 
of care that hold the highest likelihood of increasing positive patient outcomes. By 
collecting data regarding outcomes at the patient level, the PCRR stands as a unique 
resource through which to assess care process and patient outcomes in a clinically-
relevant and patient-oriented manner. This article is the first to assess this relationship 
and establishes a paradigm for future work in palliative care quality assessment work. In 
fact, the principal contribution of our work is the development of a framework through 
which we can begin to study and ultimately improve the provision of care for patients 
with life-limiting illness. We describe the types of data necessary to conduct palliative 
care quality analyses, and highlight areas where improvement is needed in future data 
collection systems. An important “proof-of-concept,” this article provides a structure that 
can be iteratively repeated over time as data quantity and quality are improved in 
community-based palliative care systems, such as the PCRR.  
In this study, we observed that dyspnea assessment at first palliative care 
consultation was routinely accomplished, but was not associated with improved 
outcomes. However, we should not interpret the latter finding to suggest that dyspnea 
assessment is a task unworthy of effort. Our inability to detect an effect on patient health 
status is likely a function of the extremely high adherence to this indicator within our 
sample. In the case of complete symptom assessment and the other indicators where 
adherence was not at a ceiling level, we are able to assess which of these lead to 
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improved outcomes and focus clinical energies there. In this case, it appears to be 
complete symptom assessment. Future priorities should be to amass a greater patient 
population in the PCRR and repeat the current analyses, which may allow us to observe 
varying levels of quality indicator adherence.  
We found that overall adherence to PEACE indicators was remarkably high for 
most indicators. For example, 99% of HF patients in our cohort were screened for 
dyspnea at their initial palliative care consultation. The primary exception was that only 
44% of patients who reported dyspnea received treatment by the end of their second 
consultation. Our findings regarding dyspnea treatment are in contrast with those of a 
somewhat similar study of cancer patients, where 73% of eligible patients received 
treatment within 24 hours.39 The Consortium is currently addressing this potential quality 
concern by implementing a rapid-cycling quality improvement initiative.   
Of the four quality indicators applicable to our entire cohort, only one indicator - 
comprehensive assessment - was found to be significantly associated with improved 
PC-PHS, when adjusting for demographic and clinical factors. Our inability to detect 
statistical significance for the remaining quality indicators merits comment. One possible 
and likely explanation is sample size. Additionally, the high rates of adherence we found 
within this sample may serve as a “ceiling effect,” limiting the degree of variation in 
adherence. Although the PCRR is the largest repository of community-based palliative 
care data in the United States, the number of HF patients was small; this finding is 
somewhat unsurprising. However, the proportion of HF patients receiving palliative care 
services appears to be increasing.40 Despite striking similarities regarding symptom 
burden4,25,41,42 and prognosis with advanced cancer patients, HF patients access 
supportive services at lower rates than do cancer patients. In 2008, cancer was the 
leading diagnosis among hospice enrollees (38.3%), whereas HF ranked 3rd (11.7%).43 
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A growing body of literature points to a variety of potential referral barriers unique to the 
HF experience as impediments to palliative care referral in this population.18,44-46 
Nevertheless, we actively sought to leverage all available data to augment the types of 
analyses that we could perform. For example, we constructed a composite outcome of 
PC-PHS and used a patient-level summary adjustment score to reduce the number of 
control variables in multivariate models. 
In the current study, we used indicators created for the palliative care and 
hospice disciplines to assess care quality. Interestingly, concurrent movements from 
within the cardiology community echo, in part, how quality health care for HF patients is 
conceptualized and defined. In 2011, the American College of Cardiology and the 
American Heart Association updated their set of performance measures to include 
symptom assessment and management.47 Advance care planning was considered for 
inclusion, as well; however, it was not ultimately adopted into the final set of measures. 
Nevertheless, efforts to coordinate perspectives regarding the needs of HF patients and 
how they can be efficiently and effectively addressed amongst the constellation of 
medical providers whom HF patients will typically encounter is paramount, given the 
multimorbidity commonly experienced by this population and the complex medical 
management that their illness necessitates.  
This study has several limitations. First, the relationship between processes of 
care and patient outcomes is complex, especially near the end of life and in the very 
elderly. Indeed, patients in our sample had a median age of 85 years, which may 
influence the specific processes of palliative care that they received, as well as the 
outcomes which they experienced. Indeed, for patients with characteristics that suggest 
greater vulnerability, it may be challenging to delineate process-outcome associations. 
Second, we were limited in our ability to control for potential confounders by both our 
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sample size and the data available in PCRR. Poisson regressions using sample sizes 
below 100 may produce wide confidence intervals.30 Importantly, our estimations of 
process-outcome associations may be biased toward the null due to missing data. For 
example, QOL assessments were missing for 41% of patients at their final palliative care 
consultation. Third, our data come from two community-based palliative care 
organizations in North Carolina, which may limit generalizability to other care settings 
and regions. Fourth, data come from a quality-monitoring database, which are likely less 
accurate and consistent than research-oriented databases, although more reflective of 
care as actually delivered in usual practice. This may introduce measurement bias, 
potentially underestimating care quality. In addition, PC-PHS was a composite measure. 
Although it has face validity, it has not been validated and may represent another source 
of measurement error.  Fifth, we did not include HF-specific quality indicators in this 
study. Finally, palliative care interventions comprise much more than the five quality 
indicators that we assessed in this study; therefore, our work may not capture the full 
effect of palliative care on patient outcomes.  
Despite these limitations, this unique database provides a glimpse into 
adherence to palliative care quality indicators in a cohort of community-dwelling HF 
patients. Despite failing to identify statistically significant associations for most indicators 
with patient outcomes, we do not suggest abandoning such intuitively appealing care 
processes. The processes assessed herein are reasonable and may contribute to better 
end-of-life care experiences, even if through indirect pathways. With the national push 
towards evidence-based medicine, work such as ours stands as a cautionary note that 
we must be judicious in our choice of data sources. The future of understanding the 
healthcare needs of HF patients in the community, as well as the ability of palliative care 
providers to meet such demands, will require a conscious effort to expand and enrich 
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data repositories such as the PCRR. Rather than serving as the basis for policy or 
practice recommendations, we suggest that our work serves as a pilot assessment of 
palliative care quality in HF. Indeed, this study further demonstrates the feasibility of data 
collection in community-based palliative care settings for the assessment of care 
quality.21 As mandated by the Patient Protection and Affordable Care Act, hospice 
organizations must begin collecting quality performance data in October 2012. 48 
Therefore, innovations to facilitate reliable and low-burden data capture of care quality in 
palliative and hospice medicine are of prime and timely interest.  
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FIGURES AND TABLES 
Figure 6.1. PEACE Palliative care quality indicators assessable within PCRR 
 
Indicator 
Frequency selected 
as a top 3 indicator 
Selected for inclusion in regression analyses  
Symptom assessment was completed during the first palliative 
care consultation 
12 
Dyspnea assessment was performed during the first palliative 
care consultation 
6 
Comprehensive assessment was completed during the first 
palliative care consultation 
5 
If patient screened positive for dyspnea during the first 
consultation, treatment for dyspnea was initiated by the end 
of consultation 2 
4 
Preferences for life-sustaining treatments were documented in 
the patient’s medical record 
4 
Not selected for inclusion in regression analyses   
An advanced directive was documented in the patient’s 
medical record 
4 
The designation of a healthcare surrogate was documented in 
the patient’s medical record 
4 
If patient screened positive for pain during the first 
consultation, treatment for pain was initiated by the end of 
consultation 2 
1 
Pain assessment was performed during the first palliative care 
consultation 
0 
Bowel function assessments were performed on a weekly 
basis 
0 
Did the patient report moderate or severe pain rating in the last 
week of life? 
0 
If patient reported pain during the first consultation, was a 
clinical assessment completed? 
0 
If treatment for pain was initiated, a reduction in pain was 
documented in the patient’s medical record 
0 
If patient screened positive for constipation during the first 
consultation, treatment for constipation was initiated by the 
end of consultation 2 
0 
Note: All indicators assessed at first palliative care consultation, unless otherwise stated. 
The quality indicator for the completion of a comprehensive assessment was defined as 
positive if the following three conditions: the clinical assessment of at least one 
symptom, assessment of quality of life, and the assessment of advance care planning 
activities. The indicators regarding advance directive documentation and healthcare 
surrogate designation were excluded based on clinical judgment, and because they 
were similar enough to the indicator regarding life-sustaining treatment preferences.  
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Table 6.1. Demographic and disease characteristics of study cohort  
 
Characteristic N (%) 
Age in years, median [range] 85 [33-101] 
Female gender 45 (53) 
Race 
    White 79 (93) 
    Black 3 (4) 
    Other or unknown 3 (4) 
Advance care planning activities completed prior to or during initial palliative care 
consultation 
   “Do not resuscitate” status declaration 59 (69) 
   Living will completed 38 (45) 
   MOST form completed 2 (2) 
   Designation of healthcare surrogate 47 (55) 
Number of recorded palliative care 
consultations, median [range] 
3 [2-24] 
Number of hospitalizations within 6 months before first palliative care consultation 
   0 12 (14) 
   1 28 (33) 
   2 15 (18) 
   3 6 (7) 
   >3 9 (11) 
   Not assessed/Unknown 15 (18) 
Care setting at the time of first palliative care consultation 
   Hospital inpatient 46 (54) 
   Nursing home or assisted living facility 21 (25) 
   Patient home 8 (9) 
   Unknown 10 (12)  
Respondent   
   Patient 54 (64)  
   Caregiver or provider 31 (37)  
    Initial Consultation,      
N (%) 
Last Consultation,  
N (%) 
Palliative Performance Scale, median 
[range] 
40 [10-80] 40 [10-60] 
   Low (10%-30%) 24 (28) 22 (26) 
   Medium (40%-60%) 41 (48) 26 (31) 
   High (70%-100%) 4 (5) -- 
   Not assessed/Unknown 16 (19) 37 (44) 
General quality of life rating    
   Poor 38 (45) 22 (26) 
   Fair 35 (41) 23 (27) 
   Good 4 (5) 5 (6) 
   Not assessed/Unknown 8 (9) 35 (41) 
Note: Values may not sum to 100 due to rounding and/or missing data. MOST = Medical 
Orders for Scope of Treatment. The Palliative Performance Scale rates functional status 
across five domains from 0-100% in 10-percentage point increments.  
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Table 6.2. Prevalence of palliative care quality indicator adherence at initial 
palliative care consultation 
 
Indicator  
Prevalence  a 
N (%) 
Full symptom assessment (i.e., 11 symptoms) at initial consultation 50/85 (59) 
Comprehensive assessment at initial consultation 72/85 (85) 
Dyspnea assessment at initial consultation 84/85 (99) 
Dyspnea treatment initiated by consultation 2, if dyspnea present at 
initial consultation 
20/45 (44) 
Documentation of life-sustaining treatment preferences at initial 
consultation 
74/85 (87) 
Overall adherence b 41/85 (48) 
a Prevalence data are reported as the number of affected patients / the number of 
eligible patients.  
b Overall adherence does not include dyspnea treatment indicator, as this applies to only 
a subset of the entire cohort.  
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Table 6.3. Outcomes of interest assessed at final palliative care consultation  
 
Characteristic N (%)  
Quality of life  
   Fair or good 28 (33) 
   Poor 22 (26) 
   Unknown 35 (41) 
Pain experience  
   Adequately-controlled or no pain 68 (80) 
   Inadequately-controlled 6 (7) 
   Unknown 11 (13) 
Dyspnea experience  
   Adequately-controlled or no dyspnea 64 (75) 
   Inadequately-controlled 8 (9) 
   Unknown  13 (15) 
Composite outcome of PC-PHS (≥2 of the above bolded outcomes)  60 (71) 
Note: The composite outcome was defined as positive if a patient having reported at 
least two of the following criteria: fair/good quality of life; adequately-controlled pain; or, 
adequately-controlled dyspnea.   
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Table 6.4. Confounder adjustment variables 
 
Variable Unadjusted RR (95% CI) 
Age per year 0.99 (0.98-1.00) 
Male gender 0.86 (0.65-1.14) 
Non-white race 0.94 (0.52-1.69) 
Patient as source of information 0.99 (0.75-1.32) 
Hospital inpatient setting of care 0.97 (0.74-1.28) 
Sum of palliative care consultations 1.01 (0.98-1.04) 
Confounder adjustment score a 3.87 (1.14-13.02) 
Abbreviations: RR, risk ratio; CI, confidence interval. 
a We calculated an adjustment score for each patient by using the equation obtained 
from a Poisson regression model that included the variables listed, in order to reduce the 
dimensionality of subsequent regressions. The adjustment score (1 variable) was used 
in the multivariable model that assessed the relationship between palliative care 
processes and terminal outcomes (Table 6.5).   
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Table 6.5. Associations between quality indicator adherence at first palliative care 
consultation and palliative care patient health status at final consultation 
 
Indicator 
 RR (95% CI)  
Unadjusted 
P-
value Adjusted a 
P-
value 
Full symptom assessment (i.e., 11 
symptoms) at initial consultation 
0.95  
(0.72-1.27) 
0.74 0.91  
(0.68-1.21) 
0.53 
Comprehensive assessment at 
initial consultation 
0.98  
(0.66-1.45) 
0.91 1.40  
(1.08-1.80) 
0.01 
Dyspnea assessment at initial 
consultation 
1.42  
(1.24-1.64) 
<0.001 1.57  
(0.93-2.64) 
0.09 
Dyspnea treatment initiated by 
consultation 2, if dyspnea 
present at initial consultation 
1.20  
(0.77-1.86) 
0.42 b  
Documentation of life-sustaining 
treatment preferences at initial 
consultation 
0.89  
(0.55-1.42) 
0.62 0.63  
(0.37-1.07) 
0.09 
Abbreviations: RR, risk ratio; CI, confidence interval.  
a Adjusted for all of the quality indicators (except for dyspnea treatment), as well as the 
unidimensional adjustment score. The adjustment score included the following factors: 
age, gender, race, patient versus proxy reporting, and care setting. The adjustment 
score had an adjusted RR (95% CI) of 3.94 (1.17-13.20), p=0.03. AIC of the adjusted 
model was 2.00, and BIC was -315.07. 
b As this indicator only represents a subset of the entire cohort, it was not assessed in 
the multivariate model due to reductions in sample size and power.  
  
 120 
REFERENCES 
 
1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics--
2010 update: a report from the American Heart Association. Circulation. Feb 23 
2010;121(7):e46-e215. 
2. Walke LM, Byers AL, Tinetti ME, Dubin JA, McCorkle R, Fried TR. Range and 
severity of symptoms over time among older adults with chronic obstructive 
pulmonary disease and heart failure. Archives of internal medicine. Dec 10 
2007;167(22):2503-2508. 
3. Bekelman DB, Havranek EP, Becker DM, et al. Symptoms, depression, and 
quality of life in patients with heart failure. J Card Fail. Oct 01 2007;13(8):643-
648. 
4. Bekelman DB, Rumsfeld JS, Havranek EP, et al. Symptom burden, depression, 
and spiritual well-being: a comparison of heart failure and advanced cancer 
patients. J Gen Intern Med. May 2009;24(5):592-598. 
5. Goodlin S, Hauptman P, Arnold R, et al. Consensus statement: palliative and 
supportive care in advanced heart failure. Journal of cardiac failure. 
2004;10(3):200-209. 
6. Goodlin S. Palliative care in congestive heart failure. J Am Coll Cardiol. Jul 28 
2009;54(5):386-396. 
7. Fonarow GC, Abraham WT, Albert NM, et al. Association between performance 
measures and clinical outcomes for patients hospitalized with heart failure. 
JAMA: The Journal of the American Medical Association. Feb 03 2007;297(1):61-
70. 
8. Hernandez AF, Hammill BG, Peterson ED, et al. Relationships between 
emerging measures of heart failure processes of care and clinical outcomes. Am 
Heart J. Apr 2010;159(3):406-413. 
9. Patterson ME, Hernandez AF, Hammill BG, et al. Process of care performance 
measures and long-term outcomes in patients hospitalized with heart failure. 
Medical care. Apr 2010;48(3):210-216. 
 121 
10. Peterson E, Roe M, Mulgund J. Association between hospital process 
performance and outcomes among patients with acute coronary syndromes. 
JAMA. 2006. 
11. Schopfer DW, Whooley MA, Stamos TD. Hospital compliance with performance 
measures and 30-day outcomes in patients with heart failure. American Heart 
Journal. Jul 2012;164(1):80-86. 
12. Unroe KT, Greiner MA, Hernandez AF, et al. Resource use in the last 6 months 
of life among medicare beneficiaries with heart failure, 2000-2007. Arch Intern 
Med. Mar 14 2011;171(3):196-203. 
13. Whellan DJ, Cox M, Hernandez AF, et al. Utilization of hospice and predicted 
mortality risk among older patients hospitalized with heart failure: findings from 
GWTG-HF. Journal of cardiac failure. Jun 2012;18(6):471-477. 
14. Meier DE, Beresford L. Outpatient clinics are a new frontier for palliative care. J 
Palliat Med. Jul 2008;11(6):823-828. 
15. Bekelman DB, Nowels CT, Allen LA, Shakar S, Kutner JS, Matlock DD. 
Outpatient Palliative Care for Chronic Heart Failure: A Case Series. J Palliat 
Med. Jul 2011;14(7):815-821. 
16. Hanratty B, Hibbert D, Mair F, et al. Doctors' understanding of palliative care. 
Palliative Medicine. Jul 01 2006;20(5):493-497. 
17. Brännström M, Forssell A, Pettersson B. Physicians' experiences of palliative 
care for heart failure patients. European Journal of Cardiovascular Nursing. Apr 
01 2011;10(1):64-69. 
18. Kavalieratos D, Mitchell EM, Carey TS, et al. Provider-related barriers impeding 
heart failure palliative care referral. Chapel Hill, North Carolina: The University of 
North Carolina at Chapel Hill; 2012. 
19. Bull J, Zafar SY, Wheeler JL, et al. Establishing a Regional, Multisite Database 
for Quality Improvement and Service Planning in Community-Based Palliative 
Care and Hospice. J Palliat Med. 2010;13(8):1013-1020. 
20. Abernethy AP, Wheeler JL, Bull J. Development of a health information 
technology-based data system in community-based hospice and palliative care. 
Am J Prev Med. May 2011;40(5 Suppl 2):S217-224. 
 122 
21. Kamal AH, Bull J, Stinson C, et al. Collecting data on quality is feasible in 
community-based palliative care. Journal of pain and symptom management. 
Nov 2011;42(5):663-667. 
22. Heidenreich PA, Sahay A, Kapoor JR, Pham MX, Massie B. Divergent trends in 
survival and readmission following a hospitalization for heart failure in the 
Veterans Affairs health care system 2002 to 2006. Journal of the American 
College of Cardiology. Jul 27 2010;56(5):362-368. 
23. Schisterman EF, Whitcomb BW. Use of the Social Security Administration Death 
Master File for ascertainment of mortality status. Popul Health Metr. Mar 5 
2004;2(1):2. 
24. Schenck AP, Rokoske FS, Durham DD, Cagle JG, Hanson LC. The PEACE 
Project: identification of quality measures for hospice and palliative care. J Palliat 
Med. Dec 2010;13(12):1451-1459. 
25. Solano J, Gomes B, Higginson I. A comparison of symptom prevalence in far 
advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease 
and renal disease. J Pain Symptom Manage. Feb 01 2006;31(1):58-69. 
26. Cohen SR, Mount BM, Strobel MG, Bui F. The McGill Quality of Life 
Questionnaire: a measure of quality of life appropriate for people with advanced 
disease. A preliminary study of validity and acceptability. Palliative Medicine. Jul 
1995;9(3):207-219. 
27. McCorkle R, Young K. Development of a symptom distress scale. Cancer Nurs. 
Oct 1978;1(5):373-378. 
28. Anderson F, Downing GM, Hill J, Casorso L, Lerch N. Palliative performance 
scale (PPS): a new tool. Journal of palliative care. Spring 1996;12(1):5-11. 
29. Mor V, Laliberte L, Morris JN, Wiemann M. The Karnofsky Performance Status 
Scale. An examination of its reliability and validity in a research setting. Cancer. 
May 1 1984;53(9):2002-2007. 
30. Zou G. A modified poisson regression approach to prospective studies with 
binary data. American Journal of Epidemiology. Apr 1 2004;159(7):702-706. 
31. McNutt L-A, Wu C, Xue X, Hafner JP. Estimating the Relative Risk in Cohort 
Studies and Clinical Trials of Common Outcomes. American Journal of 
Epidemiology. May 15, 2003 2003;157(10):940-943. 
 123 
32. Bravata DM, Wells CK, Lo AC, et al. Processes of care associated with acute 
stroke outcomes. Archives of internal medicine. May 10 2010;170(9):804-810. 
33. Arbogast PG, Kaltenbach L, Ding H, Ray WA. Adjustment for multiple 
cardiovascular risk factors using a summary risk score. Epidemiology. Jan 
2008;19(1):30-37. 
34. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per 
independent variable in proportional hazards regression analysis. II. Accuracy 
and precision of regression estimates. J Clin Epidemiol. Dec 1995;48(12):1503-
1510. 
35. Concato J, Peduzzi P, Holford TR, Feinstein AR. Importance of events per 
independent variable in proportional hazards analysis. I. Background, goals, and 
general strategy. J Clin Epidemiol. Dec 1995;48(12):1495-1501. 
36. Stata/IC [computer program]. Version 12. College Station, TX: StataCorp. 
37. Kelley AS, Morrison RS, Wenger NS, Ettner SL, Sarkisian CA. Determinants of 
Treatment Intensity for Patients with Serious Illness: A New Conceptual 
Framework. J Palliat Med. Jul 01 2010;13(7):807-813. 
38. Wennberg JE, Fisher ES, Stukel TA, Skinner JS, Sharp SM, Bronner KK. Use of 
hospitals, physician visits, and hospice care during last six months of life among 
cohorts loyal to highly respected hospitals in the United States. BMJ. Mar 13 
2004;328(7440):607. 
39. Walling AM, Asch SM, Lorenz KA, et al. The quality of supportive care among 
inpatients dying with advanced cancer. Supportive care in cancer : official journal 
of the Multinational Association of Supportive Care in Cancer. Sep 
2012;20(9):2189-2194. 
40. Kamal AH, Swetz KM, Carey EC, et al. Palliative care consultations in patients 
with cancer: a mayo clinic 5-year review. J Oncol Pract. Jan 2011;7(1):48-53. 
41. Steinhauser KE, Arnold RM, Olsen MK, et al. Comparing three life-limiting 
diseases: does diagnosis matter or is sick, sick? Journal of pain and symptom 
management. Sep 2011;42(3):331-341. 
42. O'Leary N, Murphy NF, O'Loughlin C, Tiernan E, McDonald K. A comparative 
study of the palliative care needs of heart failure and cancer patients. Eur J Heart 
Fail. Apr 2009;11(4):406-412. 
 124 
43. Andersen J. NHPCO 2009 Facts and Figures. Oct 27 2009:1-15. 
44. Hanratty B, Hibbert D, Mair F, et al. Doctors' perceptions of palliative care for 
heart failure: focus group study. BMJ. Sep 14 2002;325(7364):581-585. 
45. Green E, Gardiner C, Gott M, Ingleton C. Exploring the extent of communication 
surrounding transitions to palliative care in heart failure: the perspectives of 
health care professionals. J Palliat Care. 2011;27(2):107-116. 
46. Wotton K, Borbasi S, Redden M. When all else has failed: Nurses' perception of 
factors influencing palliative care for patients with end-stage heart failure. J 
Cardiovasc Nurs. Jan-Feb 2005;20(1):18-25. 
47. Bonow RO, Ganiats TG, Beam CT, et al. ACCF/AHA/AMA-PCPI 2011 
Performance Measures for Adults With Heart Failure: A Report of the American 
College of Cardiology Foundation/American Heart Association Task Force on 
Performance Measures and the American Medical Association-Physician 
Consortium for Performance Improvement. Circulation. Jun 15 
2012;125(19):2382-2401. 
48. MEDPAC. Hospice: Assessing payment adequacy and updating payments 
MEDPAC;2011. 
 
 
CHAPTER 7: DISCUSSION 
Overview 
HF is a prevalent, irreversible, and progressive disease affecting approximately 
5.8 million Americans, with over 550,000 annual incident cases.1 HF patients, especially 
those with advanced disease, experience physical and emotional distress during their 
course of illness;2 such distress may be addressed by palliative care. Palliative care 
focuses on the optimization of patient and family QOL regardless of disease stage or 
prognosis. Through multidisciplinary intervention, palliative care provides symptom 
management, psychological and spiritual support, and logistical assistance.3 Research 
suggests that palliative care improves satisfaction with care;4 decreases the risk of 
psychological morbidity for patients and caregivers;5,6 reduces patients’ symptom 
intensity;7 may increase survival;8 and, reduces hospital expenditures.9 However, despite 
marked similarities in symptom burden and prognosis between the two diseases in their 
advanced stages,10 HF patients and cancer patients access supportive services at 
disproportionate rates.11 Additionally, the role of specialist palliative care has yet to be 
clearly defined in cardiology, relative to the progress this discipline has made in 
substantiating its role in oncology. Furthermore, scant research is available to 
demonstrate whether palliative care improves HF patient outcomes, limiting the ability for 
palliative care advocates to call for its increased uptake in cardiac populations.   
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Study 1: Provider-related barriers impeding heart failure palliative care referral 
Previous work suggests that palliative care referral may be inhibited by several 
factors, including provider knowledge, inter-professional territorialism, organizational 
structure, and perceptions of palliative care.12-14 However, all of the aforementioned 
studies were performed in the U.K. or Australia, and therefore may have limited 
generalizability to the U.S. due to differences in healthcare delivery organization, 
reimbursement, and policies.   Our study is the first attempt to explore provider-level 
palliative care referral barriers for HF patients in the U.S. By interviewing a 
multidisciplinary and experienced group of providers, we believe to have provided a 
significant contribution to the literature regarding palliative care referral barriers in the 
U.S., some of which may not solely be specific to HF patients (and may influence 
discourse regarding non-HF populations and palliative care).   
Overall, we found that the term “palliative care” is at best ambiguous to providers, 
and at worst, misleading. Providers were confused regarding the distinction between 
non-hospice and hospice palliative care services, and frequently used terms such as 
“comfort care” or “end-of-life care” when discussing palliative care, indicating that they 
were instead referring to hospice care. This lack of clarity about palliative care was found 
regardless of clinical specialty and provider type. Notably, a majority of our sample 
consisted of academically-affiliated providers, which given the greater likelihood of 
palliative care services in such locations, suggests that our findings reflect an upward 
bias regarding palliative care knowledge. That is, we provide a “best case scenario” 
relative to providers practicing in areas without specialist palliative care services.  
Interestingly, providers in our study unanimously voiced interest in identifying 
strategies by which to integrate palliative care services into the management of their HF 
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patients. However, they voiced concern that attempts to increase knowledge amongst 
cardiology and primary care communities would need to emerge from the palliative care 
community. Palliative care providers were viewed as experts in “difficult communication,” 
and were therefore seen as the ideal agents to promote and market the role of palliative 
care amongst their primary care and cardiology colleagues. As such, future work is 
needed to understand precisely how such messages might be tailored to improve 
collaboration across clinical disciplines.  
 
Study 2: Comparing the unmet needs of community-based palliative care patients 
with heart failure and cancer 
Recognizing that barriers may exist to impede or delay the timing of palliative 
care referral among HF patients, we investigated how this might impact the way which 
HF patients ultimately present at the time of palliative care admission. That is, do HF 
patients have a greater symptom burden (frequency and severity) when seen by a 
palliative care specialist, than do cancer patients? Here, we make the assumption that 
cancer patients face fewer palliative care referral barriers due to the historical integration 
of palliative care and oncology. We capitalized on a novel quality monitoring database of 
community-based palliative care providers to study this question. 
We noted several interesting findings. First, HF patients in this study were 
significantly older than were cancer patients (median age: 84 years vs. 71 years). This 
finding is remarkable given the frailty (as indicated by performance status) and disease 
burden experienced by HF patients. This suggests that these HF patients are either 
already hospice eligible, or very near to the threshold for hospice eligibility. This finding 
in and of itself does not necessarily imply a difference in care gaps between disease 
groups, but rather strongly motivates the need for more focused research to identify the 
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underlying mechanisms that explain disparities in unmet needs across subpopulations. 
Indeed, our findings only reflect HF and cancer patients who received palliative care 
referrals. For example, patients in our study may be more acutely ill  and/or have more 
complex psychosocial needs. This may limit our ability to generalize regarding the unmet 
needs of other patients with advanced HF or cancer. Although difficult to conduct, 
population-based surveys to describe palliative care needs (met and unmet) and 
knowledge may be useful in understanding the experiences of broader populations that 
may benefit from specialist palliative care services.15  
Second, and perhaps most remarkably, despite HF patients being substantially 
older than cancer patients, their overall symptom burden reported at the time of first 
palliative care consultation was similar. Due to differences in the natural histories of the 
diseases and in characteristics of our sample, future research is needed to explore the 
factors that define effective and efficient utilization of palliative care for both HF and 
cancer populations. Particularly for diseases with notoriously unpredictable trajectories, 
such as HF,16 the timing of palliative care referral should be determined by patients’ 
needs and preferences. Future work is needed to understand how our findings translate 
to other contexts, in terms of region, practice setting, and local availability of palliative 
care services.  
 
Study 3: Assessing the quality of palliative care received by patients with heart 
failure living in the community 
Lastly, we sought to extend the literature by providing preliminary data regarding 
the association between palliative care intervention and patient-centered outcomes. 
Using a longitudinal approach, we used palliative care quality indicators to assess the 
impact of five palliative care processes performed at the first palliative care consultation 
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on outcomes measured at patients’ last palliative care consultation. This analysis was 
limited to HF patients receiving community-based palliative care services from the same 
group of providers that comprised study 2. Our outcome measure, PC-PHS, was a 
composite index that captured: fair/good QOL, adequately controlled pain, and 
adequately controlled dyspnea.  
We found remarkably high rates of adherence to most quality indicators; only one 
indicator (the receipt of a comprehensive assessment) was found to be associated with 
PC-PHS. Our inability to detect statistically significant differences may be a function of 
our relative small sample size (N = 85) and/or a “ceiling effect” due to the high rates of 
adherence seen within our sample. Ongoing efforts to improve the coverage and quality 
of data sources, such as the PCRR, are needed to measure the impact of palliative care 
services on patients with life-limiting illnesses, such as HF. Importantly, this study 
establishes a novel framework demonstrating how palliative care quality can be 
assessed through the use of patient- and proxy-reported data collected at the point-of-
care in community-dwelling patients. This framework can be iteratively repeated over 
time as the PCRR grows and is refined, and can be leveraged to answer similar 
questions in different contexts (i.e., disease states, specific quality indicators, care 
settings).   
 
Implications for policy, practice, and research 
As seen in study 2, patients with HF living in the community possess care needs 
related to their disease that merit clinical attention. Without intervention, unresolved 
symptoms may exacerbate distress experienced by both patients and their caregivers. 
As such, policy structures must be reevaluated to encourage appropriate and effective 
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utilization of palliative care services. Naturally, we must first ensure that the specialist 
palliative care landscape is prepared to care for additional patients, both in terms of 
workforce and training. Recently, the Palliative Care and Hospice Education and 
Training Act was introduced to the House Committee on Energy and Commerce.17 This 
legislation would promote educational and career opportunities for medical, osteopathic, 
and nursing providers related to palliative and hospice care.   
Additional policy mechanisms must be assessed in order to promote palliative 
care utilization by patients with advanced illness who have unmet physical and/or 
psychosocial needs. With the implementation of the Patient Protection and Affordable 
Care Act, Accountable Care Organizations (ACOs) will be responsible for the overall 
population health and wellbeing of their members. As such, they may consider 
reimbursement structures for palliative and hospice providers that address the complex 
reality of their patient populations (e.g., bundled payments). Another potential policy 
mechanism to promote palliative care would be the inclusion of palliative care providers 
within ACOs as a mandate for establishment as an ACO. Additionally, given that 
palliative care utilization may be a function of local availability, policymakers should also 
facilitate the development of palliative care services in currently underserved geographic 
regions. Furthermore, innovations in the delivery of palliative care are needed; emerging 
technologies, such as tele-palliative care (in the form of remote video-based 
consultations), may hold promise in addressing issues of geographic disparity. 
This dissertation provides preliminary evidence that collaboration between 
palliative and non-palliative care providers is suboptimal, despite mutual agreement of 
the likely benefit to patients that could result from palliative co-management or 
consultation. Graduate, postgraduate, and continuing clinical education must first be 
improved to include palliative care topics. Such training should strive to: correct 
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misconceptions about palliative care and hospice (i.e., that hospice is a specific subset 
of palliative care, largely defined by policy); teach providers how to identify palliative care 
needs in their patients; how to refer patients for specialist or consultative palliative care 
services; and how, to effectively work with palliative care providers/teams to manage 
patient and caregiver concerns. Although palliative care (specifically, community-based 
palliative care) services continue to expand within the U.S., clinical providers may benefit 
from focused training on how to provide non-specialist palliative care services 
themselves. Although specialist palliative care providers possess expertise in topics 
such as complex symptom management and difficult communication, such skills may be 
imparted to primary care and cardiology colleagues in areas without formal palliative 
care services. Lastly, lay educational efforts must seek to inform patients and caregivers 
about the existence of palliative care, taking great caution to accurately portray palliative 
and hospice services. 
Much work is still needed to create the adequate knowledge base for HF 
palliative care in order to promote policy and practice structures that would encourage 
appropriate utilization. First, given the inherent limitations of study 1 regarding sample 
size and generalizability, it is necessary that our work be replicated in other geographic 
regions and practice settings. Second, additional formative research may be needed to 
comprehensively understand how cardiology and primary care providers could be best 
educated regarding palliative care services for HF patients. Third, we explicitly focused 
our analysis on provider-level barriers to palliative care uptake; however, our neglect of 
the patient and family voice stands as its own barrier to understanding the complex 
decisions that underlie palliative care utilization. Research is critically needed to 
complement the findings we provide in study 1. Fourth, our primary outcome variable in 
studies 2 and 3, PC-PHS, is an index that we created specifically for the purposes of this 
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dissertation. An exploratory attempt to maximize the amount of information regarding 
patient-centered outcomes extracted from our data source, the PC-PHS variable’s 
psychometric properties need to be rigorously tested in future work. Although it may 
conceptually make sense as an amalgamation of factors related to patient health in 
advanced illness, the PC-PHS variable must be cautiously interpreted until we further 
investigate its validity and reliability. Fifth, future research should be conducted to 
improve the measures used to assess quality of care in community-based palliative care. 
For example, the PEACE indicators, like most research in palliative care, inherently 
reflect a cancer perspective. As such, we must be sensitive to the conclusions drawn 
from analyses of quality of care in non-cancer diseases using these indicators. Future 
research is needed to develop a framework of how to assess quality of care across 
diseases and care settings, including indicator sets. Lastly, our work in studies 2 and 3 
describe HF and cancer patients who were receiving palliative care services. As such, 
we cannot comment regarding the experiences of patients with HF and cancer who were 
not receiving palliative care from the Carolinas Consortium. It is imperative to remember 
that we cannot easily make conclusions regarding the care needs of patients with life-
limiting illness not receiving specialist palliative care services (such as those of the 
Carolinas Consortium).15 For example, it cannot be assumed that the lack of palliative 
care uptake implies that needs are currently being met, nor that patients have unmet 
needs. Patients whose care needs are relatively simple may not need specialist 
palliative care services (i.e., needs are being met without specialist palliative care), 
whereas patients not currently in specialist palliative care may be located in an area 
without such services (i.e., needs not being met). As seen from study 1, palliative care 
referral may be a function of a variety of factors (e.g., provider knowledge/attitudes, local 
culture, availability); as such, whole-population surveillance systems to understand the 
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care needs of all patients with life-limiting illness are necessary, as well as to elucidate 
provider behavior regarding palliative care referral for these patients.  
 
Conclusion 
In this three-aim, mixed methods dissertation, I explored the role of specialist 
palliative care in improving outcomes for patients with HF. Whereas the qualitative study 
provides context regarding why HF patients might not receive palliative care, the focused 
quantitative analyses of studies 2 and 3 describe the unaddressed needs and the quality 
of care ultimately received by such patients. Additionally, the sequencing of the 
individual studies strengthens the overall dissertation, as study 1 was used to inform 
study 3, thereby conveying an inclusive message regarding palliative care in the 
healthcare experiences of patients with HF. This dissertation addresses and fills prior 
gaps in the literature, both in terms of geographic scope (i.e., by performing the first 
American investigation of HF palliative care referral barriers) and types of analyses (e.g., 
by leveraging the largest database of community-based palliative care services in the 
US). Our findings suggest that at current, palliative care is not being optimally leveraged 
to support patients and families affected by HF, and that this may largely be a function of 
the timing of palliative care referral. Of course, this argument presupposes that specialist 
palliative care indeed confers benefit to HF patients, which has yet to be conclusively 
demonstrated in HF. Of note, a recent landmark randomized clinical trial of early 
outpatient palliative care in lung cancer by Temel and colleagues suggested symptom 
burden and survival benefits related to palliative care utilization.8 Similar work is 
desperately needed in HF (as well as other non-cancer diseases). Nevertheless, as a 
first step, we found that the receipt of a comprehensive assessment (defined as the 
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clinical assessment of at least one symptom, quality of life, and advance care planning 
functions) had a modest improvement in patient outcomes, while controlling for patient 
characteristics. Our work stands as an initial attempt to advance our understanding of 
why and how to leverage specialist palliative care to reduce the suffering associated with 
HF morbidity and mortality.   
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